



## Curriculum Vitae

**Amy P. Abernethy, MD PhD**



### **Table of Contents**

<i>Education and Professional Positions</i>	1
<i>Summary Biography</i>	2
<i>Honors and Distinctions</i>	3
<i>Additional Selected Career Highlights</i>	4
<i>Professional Societies</i>	5
<i>Peer-Reviewed Articles and Reports</i>	6
<i>Book Chapters</i>	41
<i>Books</i>	41
<i>Abstracts</i>	41
<i>Video and Online Presentations</i>	41
<i>Academic Responsibilities and Mentoring</i>	43
<i>Corporate Relationships</i>	48

### **Education and Professional Positions**

#### **Education:**

2013	Ph.D.	Flinders University (Medicine), Adelaide, South Australia
1994	M.D.	Duke University School of Medicine, Durham, NC, USA
1990	B.A.	University of Pennsylvania (Biochemistry), Philadelphia, PA, USA

#### **Current Professional Positions (started July 6, 2021):**

**President, Clinical Studies Platforms, Verily Life Sciences, Inc**

#### **Recent Professional Positions (ended April 23, 2021):**

**(Former) Principal Deputy Commissioner and Acting Chief Information Officer, United States Food & Drug Administration**

***Recent Professional Positions (ended January 31, 2018):***

**Chief Medical Officer, Chief Scientific Officer & Senior Vice President – Oncology, Flatiron Health, Inc.**

Adjunct Professor of Medicine, Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA

***Recent Professional Positions (ended June 30, 2015):***

**Professor of Medicine**, Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA

**Associate Professor of Nursing**, Duke University School of Nursing

**Director – Duke Center for Learning Health Care**, Duke Clinical Research Institute

**Director, Duke Cancer Care Research Program**, Duke Cancer Institute

**Licensure:**

North Carolina Medical License

Renewed August of each year until 2019

American Board of Internal Medicine:

Internal Medicine (initial certification 1997; valid through 2022)

Hospice and Palliative Medicine (initial certification 2012; valid through 2022)

Hematology and Medical Oncology (Board eligible)

## ***Summary Bibliography***

Amy P. Abernethy, MD, PhD is the President of the Clinical Studies Platforms business line at Verily, an Alphabet Company founded at the convergence of healthcare, data science and technology, building integrated solutions to improve health. In her role at Verily, Dr. Abernethy has responsibility for the company's Baseline program and other initiatives to support a broad range of clinical trials and real-world evidence (RWE) studies.

Before joining Verily in July, Dr. Abernethy was Principal Deputy Commissioner and Acting Chief Information Officer of the US Food & Drug Administration. During her tenure at the FDA, Dr. Abernethy initiated multiple critical efforts including FDA's technology and data modernization action plans and FDA's efforts to leverage real-world data & evidence to address critical questions during the COVID-19 pandemic.

Dr. Abernethy was Chief Medical Officer and Chief Scientific Officer at Flatiron Health from 2014 to early 2019. Before joining Flatiron, Dr. Abernethy was Professor of Medicine at Duke University School of Medicine, and directed the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute.

An internationally-known oncologist, health data expert and digital health leader, Dr. Abernethy has >500 publications spanning real-world data & evidence, clinical trials, patient reported outcomes, clinical informatics, health policy and patient-centered care. For more than 20 years, she has pioneered the development of technology platforms to spur novel advancements in clinical care, including the development of systems by which linked clinical data can support tracking cancer care, drug development, personalized medicine and scientific

discovery. She has served as an appointee to multiple National Academy of Medicine committees, as Chair of the Health Data Research UK International Advisory Board, on the Board of the Personalized Medicine Coalition, and President of the American Academy of Hospice & Palliative Medicine.

Dr. Abernethy went to the University of Pennsylvania as an undergraduate, and then medical school at Duke, where she also did her Internal Medicine residency, a year as Chief Resident, and her hematology/oncology fellowship. She has her PhD from Flinders University in Australia, focused on evidence-based medicine.

## ***Honors and Distinctions***

1990	Helix Prize in Biochemistry, University of Pennsylvania
1992 – 1993	<b>Howard Hughes Medical Institute</b> , Research Training Fellowship
1993	<b>Alpha Omega Alpha</b> , National Medical Honor Society
1994	<b>Hewlett Packard Prize for Combined Excellence in Clinical Medicine and Basic Science</b> , Duke University School of Medicine
1996 – 1997	Assistant Chief Resident, Internal Medicine, Duke University Medical Center
1998 – 1999	Greenfield Scholar, Duke University Medical Center
1998 – 1999	<b>Chief Resident, Internal Medicine</b> , Duke University Medical Center
1999	<b>Davison Society Excellence in Teaching Award</b> , Duke University School of Medicine
1999 – 2001	National Institutes of Health Training Grant
2001 – 2006	<b>Doris Duke Charitable Foundation Clinical Scientist Development Award</b>
2003	Pfizer Clinical Research Prize in Medicine, Flinders University of South Australia
2005 – 2011	Elected, Academic Council, Duke University
2005	<b>General Medicine Attending Teaching Award</b> , Department of Medicine, Durham Regional Hospital, Duke University Health System
2007	<b>Malek Cancer Research Scientist Award</b> , Duke Comprehensive Cancer Center
2007	<b>Cancer Center Young Investigator Award</b> , Duke Comprehensive Cancer Center
2007	<b>Elected, Fellow of the American Academy of Hospice and Palliative Medicine (FAAHPM)</b>
2007 – 2009	<b>Elected, Executive Committee of the Academic Council, Duke University</b>
2008 – 2010	Interim Program Leader, Cancer Prevention, Detection and Control Program, Duke Comprehensive Cancer Center
2009 – 2015	<b>Elected, Board of Directors (Director-at-Large), American Academy of Hospice and Palliative Medicine</b>
2009	Nominated, 2009 Leonard Palumbo, Jr. M.D. Faculty Achievement Award, Duke University School of Medicine
2009	Nominated, 2009 Clinical Research Mentoring Award, Duke University School of Medicine

2010	<b>Elected, Fellow of the American College of Physicians (FACP)</b>
2010 – 2013	Appointed, External Advisory Board, Total Cancer Care, Moffitt Cancer Center, Tampa, FL (committee sunsetted)
2010 – 2015	Appointed, <b>Co-Chair, Palliative Care Research Cooperative Group</b> (funded by National Institute for Nursing Research)
2010	Duke Talent Identification Program 2010 Distinguished Alumni Award
2010 – 2014	Appointed, Friends of Cancer Research Comparative Effectiveness Research Advisory Committee
2011 – present	<b>Appointed, National Cancer Policy Forum, National Academy of Medicine</b> (formerly the Institute of Medicine) <sup>1</sup>
2011 – 2012	Appointed, Panel for Provisional Clinical Opinion on Palliative Care, American Society of Clinical Oncology
2011 – present	<b>Elected, Board of Directors of the Personalized Medicine Coalition; Elected Secretary, 2013</b> ; re-elected to the Board in 2018 after a brief 6-month hiatus
2012 – 2015	<b>Elected, President, American Academy of Hospice &amp; Palliative Medicine</b> (President-Elect March 2012-2013; President March 2013-2014; Immediate Past President March 2014-2015)
2012	<b>2012 Ruth and A. Morris Williams Faculty Research Prize</b> for clinical science research, Duke University School of Medicine
2012	American Academy of Hospice & Palliative Medicine Distinguished Service Award
2012 – 2014	Appointed, Chair, Health Policy Task Force, American Association for Cancer Research
2013 – present	<b>Elected into the American Society for Clinical Investigation (ASCI)</b>
2016	American Academy of Hospice & Palliative Medicine Award for Excellence in Scientific Research in Palliative Care
2020	<b>Innovation in Regulatory Science Leadership Award</b> , Reagan-Udall Foundation, December 2020

### ***Additional Selected Career Highlights***

1994 – 1997	Medical Residency, Internal Medicine, Duke University Medical Center
1997 – 2001	Fellowship in Hematology/Medical Oncology, Duke University
1998 – 1999	Chief Resident, Internal Medicine, Duke University and Durham Veterans Affairs Medical Centers, Durham NC
2001 – 2003	Research Associate, Hematology/Medical Oncology, Duke University Medical Center, Durham, NC
2003 – 2009	Assistant Professor of Medicine, Hematology/Medical Oncology, Duke University Medical Center
2005 – 2015	Director, Duke Cancer Care Research Program, Duke Cancer Institute
2007 – 2009	Assistant Professor of Nursing, Duke University School of Nursing

<sup>1</sup> At large appointment to the National Cancer Policy Form from 2011 to 2017, and transition to a Flatiron Health nominated position in

2009 – 2014	Associate Professor of Medicine, with Tenure, Division of Medical Oncology, Duke University School of Medicine
2009 – 2014	Adjunct Associate Professor, Health Policy & Management, Gillings School of Global Public Health, Univ. of North Carolina, Chapel Hill, NC
2009 – 2015	Associate Professor of Nursing, Duke University School of Nursing
2008 – 2010	Associate Director – Population Sciences, and Acting Program Leader – Cancer Control Program, Duke Comprehensive Cancer Center
2008 – 2010	Medical Director, Cancer Care Quality and Patient-centered Outcomes, Duke Cancer Institute, Duke University Health System
2012 – 2015	Director, Center for Learning Health Care, Duke Clinical Research Institute
2014 – 2015	Professor of Medicine, with Tenure, Division of Medical Oncology, Duke University School of Medicine
2014 – 2018	Adjunct Professor, Health Policy & Management, Gillings School of Global Public Health, Univ. of North Carolina, Chapel Hill, NC <sup>2</sup>
2014 – 2019	Chief Medical Officer and Senior Vice President for Oncology, Flatiron Health, Inc, New York, New York; added role of Chief Scientific Officer in February 2015
2015 – 2018	Adjunct Professor of Medicine, Division of Medical Oncology, Department of Medicine, Duke University School of Medicine
2018 – 2021	Principal Deputy Commissioner, US Food and Drug Administration
2018 – 2021	Acting Chief Information Officer, US Food and Drug Administration
2021 --	President, Clinical Research Platforms, Verily Life Sciences

### **Scholarly Societies:**

1993	Alpha Omega Alpha
2013	American Society for Clinical Investigation

### **Professional Societies**

#### **American Association for Cancer Research**

Member, Cancer Science Policy & Legislative Affairs Committee, 2011 – 2015  
Chair, Health Policy Task Force, 2012 – 2014

#### **American Academy of Hospice and Palliative Medicine**

Editor-in-Chief, *PC-FACS*, 2005 - 2012  
Chair, Publication/Product Assessment Task Force, 2008-2009  
Chair, Clinical Education Committee, 2009 – 2012  
Director-at-Large, Board of Directors, 2009 – 2012  
Section Editor, *J Pain & Symptom Management*, 2009 – 2012  
Advisory Board, *J Pain & Symptom Management*, 2012 – 2015  
President (President-Elect, President, Immediate Past President), 2012 – 2015  
Associate Editor, *PC-FACS*, 2012 – 2015

#### **American College of Physicians**

#### **American Medical Association**

American Psychosocial Oncology Society

#### **American Society of Clinical Oncology**

Member, Clinical Practice Guidelines Committee (CPGC), 2010 – 2013  
Chair and Member, CancerLinQ Advisory Committee, 2011 – 2014  
Member, Panel for Provisional Clinical Opinion on Palliative Care, 2011 – 2012  
Member, Healthplan Policy Review Advisory Group, 2011 – 2013

---

<sup>2</sup> End-date unclear

Member, Provider-Payer Initiative Workgroup, 2011 - 2013  
 Member, Cancer Education Committee (CEC), Annual Meeting & Disease-Specific Small Meetings Subcommittee (Ethics), 2011 – 2015  
 Representative to ACORD Workshop, Australia, 2010 and 2012  
 Editorial Board, Journal of Oncology Practice, 2011 – 2013  
 Cochrane Collaboration, Pain, Palliative and Supportive Care Group  
 European Association of Palliative Care  
 International Association for the Study of Pain  
 International Society for Pharmacoeconomics and Outcomes Research  
 Multinational Association for Supportive Care in Cancer  
 Chair, Quality of Life Study Group, 2009-2011  
 National Comprehensive Cancer Network  
 Member, Fatigue NCCN Guidelines Panel, 2007 – 2013  
 Member, Pain NCCN Guidelines Panel, 2010 – 2012  
 National Hospice and Palliative Care Organization  
 Member, Research Committee, 2008 – 2010  
**Personalized Medicine Coalition**  
 Elected member, Board of Directors, 2011 – 2018 (brief hiatus in 2018)  
 Secretary, Executive Committee, 2013 – 2018

#### **Cooperative Groups and Network Membership:**

2007 – 2015 Alliance (formerly, Cancer and Leukemia Group B (CALGB)), National Cancer Institute, Member; CTEP number 41447  
 2010 – 2015 Palliative Care Research Cooperative Group (PCRC), National Institute for Nursing Research, Co-Chair, Co-Principal Investigator and Founding Member

#### **Peer-Reviewed Articles and Reports**

1. Brenowitz M, Mandal N, **Pickar A**, Jamison E, Adhya S. DNA-binding properties of a lac repressor mutant incapable of forming tetramers. *J Biol Chem*. Jan 15 1991;266(2):1281-1288.
2. Brenowitz M, **Pickar A**, Jamison E. Stability of a Lac repressor mediated "looped complex". *Biochemistry*. Jun 18 1991;30(24):5986-5998.
3. **Abernethy AP**, Phillips PA, Currow DC. Applying the evidence to improve the quality of our system of cancer care: what do the words mean? [Review]. *Cancer Forum*. 2001;5:109-111.
4. Abbott KH, Sago JG, Breen CM, **Abernethy AP**, Tulsky JA. Families looking back: one year after discussion of withdrawal or withholding of life-sustaining support. *Crit Care Med*. Jan 2001;29(1):197-201.
5. Breen CM, **Abernethy AP**, Abbott KH, Tulsky JA. Conflict associated with decisions to limit life-sustaining treatment in intensive care units. *J Gen Intern Med*. May 2001;16(5):283-289.
6. **Abernethy AP**, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. *BMJ*. Sep 6 2003;327(7414):523-528. 10.1136/bmj.327.7414.523
7. **Abernethy AP**, Samsa GP, Matchar DB. A clinical decision and economic analysis model of cancer pain management. *Am J Manag Care*. Oct 2003;9(10):651-664.

8. Currow DC, **Abernethy AP**, Frith P. Morphine for the management of refractory dyspnoea [Letter]. *BMJ*. 2003;327(7426):1288-1289.
9. Currow DC, **Abernethy AP**, Fazekas BS. Specialist palliative care needs of whole populations: a feasibility study using a novel approach. *Palliat Med*. Apr 2004;18(3):239-247.
10. Stevenson J, **Abernethy AP**, Miller C, Currow DC. Managing comorbidities in patients at the end of life [Review]. *BMJ*. Oct 16 2004;329(7471):909-912. 10.1136/bmj.329.7471.909
11. **Abernethy AP**, Keefe FJ, McCrory DC, Scipio CD, Matchar DB. *Technology assessment on the use of behavioral therapies for treatment of medical disorders: part 2 - impact on management of patients with cancer pain*. Rockville, MD: United States Agency for Healthcare Research and Quality;2005. <http://archive.ahrq.gov/clinic/techarch.htm>
12. **Abernethy AP**, McCrory DC. *Technology Assessment: Report on the relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: Part 2 – Imatinib for gastrointestinal stromal cell tumors (GIST)*. Rockville, MD: United States Agency for Healthcare Research and Quality;2005. <http://archive.ahrq.gov/clinic/ta/gist/>
13. **Abernethy AP**, McCrory DC. *Technology Assessment: Report on the relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: Part 3 – Imatinib for chronic myeloid leukemia*. Rockville, MD: United States Agency for Healthcare Research and Quality;2005. <http://archive.ahrq.gov/clinic/ta/cml/>
14. **Abernethy AP**, McCrory DC. *Technology Assessment: Report on the relative efficacy of oral cancer therapy for Medicare beneficiaries versus currently covered therapy: Part 4- Thalidomide for multiple myeloma*. Rockville, MD: United States Agency for Healthcare Research and Quality;2005. <http://archive.ahrq.gov/clinic/ta/thalidomide/>
15. **Abernethy AP**, Currow DC, Frith P, Fazekas B. Prescribing palliative oxygen: a clinician survey of expected benefit and patterns of use [Letter]. *Palliat Med*. Mar 2005;19(2):168-170.
16. **Abernethy AP**, Shelby-James T, Fazekas BS, Woods D, Currow DC. The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice [ISRCTN81117481]. *BMC Palliat Care*. Nov 12 2005;4:7. 10.1186/1472-684X-4-7
17. Mitchell GK, **Abernethy AP**. A comparison of methodologies from two longitudinal community-based randomized controlled trials of similar interventions in palliative care: what worked and what did not? *J Palliat Med*. Dec 2005;8(6):1226-1237. 10.1089/jpm.2005.8.1226
18. Tieman JJ, **Abernethy AP**, Fazekas BS, Currow DC. CareSearch: finding and evaluating Australia's missing palliative care literature. *BMC Palliat Care*. Aug 8 2005;4:4. 10.1186/1472-684X-4-4
19. Keefe FJ, **Abernethy AP**, L CC. Psychological approaches to understanding and treating disease-related pain [Review]. *Annu Rev Psychol*. 2005;56:601-630. 10.1146/annurev.psych.56.091103.070302
20. Cox CE, Govert JA, Shanawani H, **Abernethy AP**. Providing palliative care for patients receiving mechanical ventilation. Part 1: invasive and non-invasive ventilation [Review]. *Progress Palliat Care*. 2005;13(2):63-69.
21. Cox CE, Govert JA, Shanawani H, **Abernethy AP**. Providing palliative care for patients receiving mechanical ventilation in an intensive care unit part 2: withdrawing ventilation [Review]. *Progress Palliat Care*. 2005;13(3):133-137.
22. Currow DC, **Abernethy AP**. Quality palliative care: practitioners' needs for dynamic

lifelong learning [Letter]. *J Pain Symptom Manage*. Apr 2005;29(4):332-334.  
10.1016/j.jpainsymman.2005.02.005

**23. Abernethy AP**, Arnold RM. PC-FACS: a real-time evidence resource for busy palliative care clinicians [Editorial]. *J Palliat Med*. Feb 2006;9(1):24-28. 10.1089/jpm.2006.9.24

**24. Abernethy AP**, Currow DC, Hunt R, Williams H, Roder-Allen G, Rowett D, Shelby-James T, Esterman A, May F, Phillips PA. A pragmatic 2 x 2 x 2 factorial cluster randomized controlled trial of educational outreach visiting and case conferencing in palliative care-methodology of the Palliative Care Trial [ISRCTN 81117481]. *Contemp Clin Trials*. Feb 2006;27(1):83-100. 10.1016/j.cct.2005.09.006

**25. Currow DC, Abernethy AP**, Shelby-James TM, Phillips PA. The impact of conducting a regional palliative care clinical study. *Palliat Med*. Dec 2006;20(8):735-743.  
10.1177/0269216306072346

**26. Sladek R, Tieman J, Fazekas BS, Abernethy AP**, Currow DC. Development of a subject search filter to find information relevant to palliative care in the general medical literature. *J Med Libr Assoc*. Oct 2006;94(4):394-401.

**27. Currow DC, Abernethy AP**. Reader questions benefit of nebulized opioids [Letter]. *Oncol Nurs Forum*. May 2006;33(3):513; author reply 513-514.

**28. Uronis HE, Currow DC, Abernethy AP**. Palliative management of refractory dyspnea in COPD [Review]. *Int J Chron Obstruct Pulmon Dis*. 2006;1(3):289-304.

**29. Currow D, Abernethy AP**. A framework for managing comorbid conditions in palliative care [Letter]. *J Palliat Med*. Jun 2006;9(3):620; authors reply 621-622. 10.1089/jpm.2006.9.620

**30. Currow DC, Abernethy AP**. Frameworks for approaching prescribing at the end of life [Letter]. *Arch Intern Med*. Nov 27 2006;166(21):2404. 10.1001/archinte.166.21.2404-a

**31. Shelby-James T, Abernethy AP**, Currow DC. Evidence in palliative care research: how should it be gathered? [Letter]. *Med J Aust*. Feb 20 2006;184(4):196-197.

**32. Currow DC, Abernethy AP**. The broader implications of diabetes management at the end of life [Letter]. *Palliat Med*. Sep 2006;20(6):638-639. 10.1177/026921630602000604

**33. Koropchak CM, Pollak KI, Arnold RM, Alexander SC, Skinner CS, Olsen MK, Jeffreys AS, Rodriguez KL, Abernethy AP**, Tulskey JA. Studying communication in oncologist-patient encounters: the SCOPE Trial. *Palliat Med*. Dec 2006;20(8):813-819.  
10.1177/0269216306070657

**34. Martin MG, Ardati AK, Dunlay SM, Abernethy AP**, Blazing MA. Small cell lung cancer presenting as a paraneoplastic syndrome characterized by recurrent episodic hypotension and bradycardia: case report. *Chest*. Jan 2007;131(1):290-293. 10.1378/chest.06-1281

**35. Shelby-James TM, Abernethy AP**, McAlindon A, Currow DC. Handheld computers for data entry: high tech has its problems too. *Trials*. 2007;8:5. 10.1186/1745-6215-8-5

**36. Friedman DR, Abernethy AP**. Review of targeted cancer therapies for the palliative care provider: part 1: small molecules [Review]. *Progress Palliat Care*. 2007;15(4):171-176.

**37. Friedman DR, Abernethy AP**. Review of targeted cancer therapies for palliative care provider. Part 2: antibodies and conjugated agents [Review]. *Progress Palliat Care*. 2007;15(4):171-176.

**38. Currow DC, Stevenson JP, Abernethy AP**, Plummer J, Shelby-James TM. Prescribing in palliative care as death approaches. *J Am Geriatr Soc*. Apr 2007;55(4):590-595.



10.1111/j.1532-5415.2007.01124.x

39. Dixon KE, Keefe FJ, Scipio CD, Perri LM, **Abernethy AP**. Psychological interventions for arthritis pain management in adults: a meta-analysis. *Health Psychol*. May 2007;26(3):241-250. 10.1037/0278-6133.26.3.241
40. Stevenson JP, Currow DC, **Abernethy AP**. Frameworks for prescribing in comorbid illness [Letter]. *J Pain Symptom Manage*. Aug 2007;34(2):117-118. 10.1016/j.jpainsymman.2007.04.013
41. Currow DC, Fazekas B, **Abernethy AP**. Oxygen use--patients define symptomatic benefit discerningly [Letter]. *J Pain Symptom Manage*. Aug 2007;34(2):113-114. 10.1016/j.jpainsymman.2007.03.004
42. **Abernethy AP**, Hanson LC, Main DS, Kutner JS. Palliative care clinical research networks, a requirement for evidence-based palliative care: time for coordinated action [Editorial]. *J Palliat Med*. Aug 2007;10(4):845-850. 10.1089/jpm.2007.0044
43. Currow DC, **Abernethy AP**. Pharmacological management of dyspnoea [Review]. *Curr Opin Support Palliat Care*. Aug 2007;1(2):96-101. 10.1097/SPC.0b013e3282ef5e03
44. Stevenson JP, Currow DC, **Abernethy AP**. The broader implications of managing statins at the end of life [Letter]. *J Palliat Care*. Autumn 2007;23(3):188-189; author reply 189.
45. Castel LD, **Abernethy AP**, Li Y, Depuy V, Saville BR, Hartmann KE. Hazards for pain severity and pain interference with daily living, with exploration of brief pain inventory cutpoints, among women with metastatic breast cancer. *J Pain Symptom Manage*. Oct 2007;34(4):380-392. 10.1016/j.jpainsymman.2006.12.007
46. Currow DC, Plummer J, Frith P, **Abernethy AP**. Can we predict which patients with refractory dyspnea will respond to opioids? *J Palliat Med*. Oct 2007;10(5):1031-1036. 10.1089/jpm.2007.9912
47. Shelby-James TM, Currow DC, Phillips PA, Williams H, **Abernethy AP**. Promoting patient centred palliative care through case conferencing. *Aust Fam Physician*. Nov 2007;36(11):961-964.
48. Friedman JY, Curtis LH, Hammill BG, Dhillon JK, Weaver CH, Biswas S, **Abernethy AP**, Schulman KA. The Medicare Modernization Act and reimbursement for outpatient chemotherapy: do patients perceive changes in access to care? *Cancer*. Nov 15 2007;110(10):2304-2312. 10.1002/cncr.23042
49. Pollak KI, Arnold RM, Jeffreys AS, Alexander SC, Olsen MK, **Abernethy AP**, Sugg Skinner C, Rodriguez KL, Tulskey JA. Oncologist communication about emotion during visits with patients with advanced cancer. *J Clin Oncol*. Dec 20 2007;25(36):5748-5752. 10.1200/JCO.2007.12.4180
50. Currow DC, Agar M, Sanderson C, **Abernethy AP**. Populations who die without specialist palliative care: does lower uptake equate with unmet need? *Palliat Med*. Jan 2008;22(1):43-50. 10.1177/0269216307085182
51. Currow DC, Agar M, Tieman J, **Abernethy AP**. Multi-site research allows adequately powered palliative care trials; web-based data management makes it achievable today [Editorial]. *Palliat Med*. Jan 2008;22(1):91-92. 10.1177/0269216307085083
52. Castel LD, Saville BR, Depuy V, Godley PA, Hartmann KE, **Abernethy AP**. Racial differences in pain during 1 year among women with metastatic breast cancer: a hazards analysis of interval-censored data. *Cancer*. Jan 1 2008;112(1):162-170. 10.1002/cncr.23133

53. Uronis HE, Currow DC, McCrory DC, Samsa GP, **Abernethy AP**. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis. *Br J Cancer*. Jan 29 2008;98(2):294-299. 10.1038/sj.bjc.6604161
54. **Abernethy AP**, Uronis HE, Wheeler JL, Currow DC. Pharmacological management of breathlessness in advanced disease [Review]. *Progress Palliat Care*. 2008;16(1):15-20.
55. Clark K, Currow DC, Agar M, Fazekas BS, **Abernethy AP**. A pilot phase II randomized, cross-over, double-blinded, controlled efficacy study of octreotide versus hyoscine hydrobromide for control of noisy breathing at the end-of-life. *J Pain Palliat Care Pharmacother*. 2008;22(2):131-138.
56. Clay AS, **Abernethy AP**. Total parenteral nutrition for patients with advanced life-limiting cancer: decision-making in the face of conflicting evidence [Review]. *Progress Palliat Care*. 2008;16(2):69-77.
57. Currow DC, Allen K, Plummer J, Aoun S, Hegarty M, **Abernethy AP**. Bereavement help-seeking following an 'expected' death: a cross-sectional randomised face-to-face population survey. *BMC Palliat Care*. 2008;7:19. 10.1186/1472-684X-7-19
58. Currow DC, Ward A, Clark K, Burns CM, **Abernethy AP**. Caregivers for people with end-stage lung disease: characteristics and unmet needs in the whole population. *Int J Chron Obstruct Pulmon Dis*. 2008;3(4):753-762.
59. **Abernethy AP**, **Currow DC**. Culture and financing influence palliative care services, study populations, and generalizability of research findings [Letter]. *J Palliat Med*. Mar 2008;11(2):146. 10.1089/jpm.2008.9978
60. Grote T, Hughes AH, Rimmer CC, Less DA, **Abernethy AP**. Targeting lymph node retrieval and assessment in stage II colon cancer: a quality outcome community-based cancer center study. *J Oncol Pract*. Mar 2008;4(2):55-58. 10.1200/JOP.0822001
61. Keefe F, **Abernethy AP**, Wheeler J, Affleck G. Don't ask, don't tell? Revealing placebo responses to research participants and patients [Editorial]. *Pain*. Apr 2008;135(3):213-214. 10.1016/j.pain.2008.01.009
62. **Abernethy AP**, Wheeler JL, Fortner BV. A health economic model of breakthrough pain [Review]. *Am J Manag Care*. May 2008;14(5 Suppl 1):S129-140.
63. Butt Z, Rosenbloom SK, **Abernethy AP**, Beaumont JL, Paul D, Hampton D, Jacobsen PB, Syrjala KL, Von Roenn JH, Cella D. Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. *J Natl Compr Canc Netw*. May 2008;6(5):448-455.
64. **Abernethy AP**, Currow DC, Fazekas BS, Luszcz MA, Wheeler JL, Kuchibhatla M. Specialized palliative care services are associated with improved short- and long-term caregiver outcomes. *Support Care Cancer*. Jun 2008;16(6):585-597. 10.1007/s00520-007-0342-8
65. **Abernethy AP**, Wheeler JL. Total dyspnoea. *Curr Opin Support Palliat Care*. Jun 2008;2(2):110-113. 10.1097/SPC.0b013e328300cad0
66. Uronis HE, **Abernethy AP**. Oxygen for relief of dyspnea: what is the evidence? [Review]. *Curr Opin Support Palliat Care*. Jun 2008;2(2):89-94. 10.1097/SPC.0b013e3282ff0f5d
67. **Abernethy AP**. Pain and sleep: establishing bi-directional association in a population-based sample [Editorial]. *Pain*. Jul 2008;137(1):1-2. 10.1016/j.pain.2008.03.022
68. Shea AM, Curtis LH, Hammill BG, DiMartino LD, **Abernethy AP**, Schulman KA.

Association between the Medicare Modernization Act of 2003 and patient wait times and travel distance for chemotherapy. *JAMA*. Jul 9 2008;300(2):189-196. 10.1001/jama.300.2.189

69. Campbell MK, Mayer D, **Abernethy A**, Carroll S. Cancer survivorship [Review]. *N C Med J*. Jul-Aug 2008;69(4):322-324.

70. Grbich C, **Abernethy AP**, Shelby-James T, Fazekas B, Currow DC. Creating a research culture in a palliative care service environment: a qualitative study of the evolution of staff attitudes to research during a large longitudinal controlled trial (ISRCTN81117481). *J Palliat Care*. Summer 2008;24(2):100-109.

71. Currow DC, Burns CM, **Abernethy AP**. Financial burden of caring until the end of life [Letter]. *Intern Med J*. Sep 2008;38(9):745. 10.1111/j.1445-5994.2008.01768.x

72. Currow DC, Christou T, Smith J, Carmody S, Lewin G, Aoun S, **Abernethy AP**. Do terminally ill people who live alone miss out on home oxygen treatment? An hypothesis generating study. *J Palliat Med*. Sep 2008;11(7):1015-1022. 10.1089/jpm.2008.0016

73. Robinson TM, Alexander SC, Hays M, Jeffreys AS, Olsen MK, Rodriguez KL, Pollak KI, **Abernethy AP**, Arnold R, Tulskey JA. Patient-oncologist communication in advanced cancer: predictors of patient perception of prognosis. *Support Care Cancer*. Sep 2008;16(9):1049-1057. 10.1007/s00520-007-0372-2

74. Currow DC, Burns CM, **Abernethy AP**. Place of death for people with noncancer and cancer illness in South Australia: a population-based survey. *J Palliat Care*. Autumn 2008;24(3):144-150.

75. Agar M, Currow DC, Shelby-James TM, Plummer J, Sanderson C, **Abernethy AP**. Preference for place of care and place of death in palliative care: are these different questions? *Palliat Med*. Oct 2008;22(7):787-795. 10.1177/0269216308092287

76. Currow DC, Ward AM, Plummer JL, Bruera E, **Abernethy AP**. Comfort in the last 2 weeks of life: relationship to accessing palliative care services. *Support Care Cancer*. Nov 2008;16(11):1255-1263. 10.1007/s00520-008-0424-2

77. Zafar SY, Currow D, **Abernethy AP**. Defining best supportive care [Letter]. *J Clin Oncol*. Nov 1 2008;26(31):5139-5140. 10.1200/JCO.2008.19.7491

78. Zafar SY, **Abernethy AP**, Abbott DH, Grambow SC, Marcello JE, Herndon JE, 2nd, Rowe KL, Kolimaga JT, Zullig LL, Patwardhan MB, Provenzale DT. Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems. *BMC Cancer*. 2008;8:345. 10.1186/1471-2407-8-345

79. **Abernethy AP**, Herndon JE, 2nd, Wheeler JL, Patwardhan M, Shaw H, Lyerly HK, Weinfurt K. Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data. *Health Serv Res*. Dec 2008;43(6):1975-1991. 10.1111/j.1475-6773.2008.00887.x

80. **Abernethy A**, Burns C, Wheeler J, Currow D. Defining distinct caregiver subpopulations by intensity of end-of-life care provided. *Palliat Med*. Jan 2009;23(1):66-79. 10.1177/0269216308098793

81. Currow DC, To T, **Abernethy AP**. Prescribing at times of clinical transition in chronic or progressive diseases [Review]. *International Journal of Gerontology*. 2009;3(1):1-8.

82. Zafar SY, Alexander SC, Weinfurt KP, Schulman KA, **Abernethy AP**. Decision making and quality of life in the treatment of cancer: a review [Review]. *Support Care Cancer*. Feb 2009;17(2):117-127. 10.1007/s00520-008-0505-2

83. **Abernethy AP**, Wheeler JL, Zafar SY. Detailing of gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, new insights, and a proposed approach [Review]. *Curr Opin Support Palliat Care*. Mar 2009;3(1):41-49. 10.1097/SPC.0b013e32832531ce
84. Currow DC, Wheeler JL, Glare PA, Kaasa S, **Abernethy AP**. A framework for generalizability in palliative care. *J Pain Symptom Manage*. Mar 2009;37(3):373-386. 10.1016/j.jpainsymman.2008.03.020
85. **Abernethy AP**, Raman G, Balk EM, Hammond JM, Orlando LA, Wheeler JL, Lau J, McCrory DC. Systematic review: reliability of compendia methods for off-label oncology indications. *Ann Intern Med*. Mar 3 2009;150(5):336-343.
86. Agar M, Currow D, Plummer J, Seidel R, Carnahan R, **Abernethy AP**. Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. *Palliat Med*. Apr 2009;23(3):257-265. 10.1177/0269216309102528
87. Dorman S, Jolley C, **Abernethy A**, Currow D, Johnson M, Farquhar M, Griffiths G, Peel T, Moosavi S, Byrne A, Wilcock A, Alloway L, Bausewein C, Higginson I, Booth S. Researching breathlessness in palliative care: consensus statement of the National Cancer Research Institute Palliative Care Breathlessness Subgroup. *Palliat Med*. Apr 2009;23(3):213-227. 10.1177/0269216309102520
88. Hendrix CC, **Abernethy A**, Sloane R, Misuraca J, Moore J. A pilot study on the influence of an individualized and experiential training on cancer caregiver's self-efficacy in home care and symptom management. *Home Healthc Nurse*. May 2009;27(5):271-278.
89. Dupont A, Wheeler J, Herndon JE, 2nd, Coan A, Zafar SY, Hood L, Patwardhan M, Shaw HS, Lysterly HK, **Abernethy AP**. Use of tablet personal computers for sensitive patient-reported information. *J Support Oncol*. May-Jun 2009;7(3):91-97.
90. **Abernethy AP**, Barbour SY, Uronis H, Zafar SY, Coan A, Rowe K, Pupa MR, Wheeler JL, Herndon JE, 2nd. Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center. *Support Care Cancer*. Jun 2009;17(6):735-744. 10.1007/s00520-008-0562-6
91. **Abernethy AP**, Herndon JE, 2nd, Wheeler JL, Day JM, Hood L, Patwardhan M, Shaw H, Lysterly HK. Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology. *J Pain Symptom Manage*. Jun 2009;37(6):1027-1038. 10.1016/j.jpainsymman.2008.07.011
92. Currow DC, **Abernethy AP**. Ideas whose times have come [Editorial]. *Curr Opin Support Palliat Care*. Jun 2009;3(2):91-92. 10.1097/SPC.0b013e32832b25e5
93. Currow DC, Agar M, Smith J, **Abernethy AP**. Does palliative home oxygen improve dyspnoea? A consecutive cohort study. *Palliat Med*. Jun 2009;23(4):309-316. 10.1177/0269216309104058
94. Currow DC, Ward AM, **Abernethy AP**. Advances in the pharmacological management of breathlessness [Review]. *Curr Opin Support Palliat Care*. Jun 2009;3(2):103-106. 10.1097/SPC.0b013e32832b37fa
95. Sprangers MA, Sloan JA, Veenhoven R, Cleeland CS, Halyard MY, **Abernethy AP**, Baas F, Barsevick AM, Bartels M, Boomsma DI, Chauhan C, Dueck AC, Frost MH, Hall P, Klepstad P, Martin NG, Miaskowski C, Mosing M, Movsas B, Van Noorden CJ, Patrick DL, Pedersen NL, Ropka ME, Shi Q, Shinozaki G, Singh JA, Yang P, Zwiderman AH. The

establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. *Twin Res Hum Genet.* Jun 2009;12(3):301-311. 10.1375/twin.12.3.301

**96. Abernethy AP**, Herndon JE, Wheeler JL, Rowe K, Marcello J, Patwardhan M. Poor documentation prevents adequate assessment of quality metrics in colorectal cancer. *J Oncol Pract.* Jul 2009;5(4):167-174. 10.1200/JOP.0942003

**97. Abernethy AP**, Allen Lapointe NM, Wheeler JL, Irvine RJ, Patwardhan M, Matchar DB. *Technology Assessment: Horizon scan - to what extent do changes in third-party payment affect clinical trials and the evidence base?* Rockville, MD: United States Agency for Healthcare Research and Quality; Aug 2009.  
<http://www.cms.hhs.gov/determinationprocess/downloads/id67aTA.pdf>

**98. Fleming ND**, Alvarez-Secord A, Von Gruenigen V, Miller MJ, **Abernethy AP**. Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. *J Pain Symptom Manage.* Sep 2009;38(3):341-349. 10.1016/j.jpainsymman.2008.09.008

**99. Zafar SY**, Marcello JE, Wheeler JL, Rowe KL, Morse MA, Herndon JE, **Abernethy AP**. Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. *J Oncol Pract.* Sep 2009;5(5):228-233. 10.1200/JOP.091010

**100. Currow DC**, Plummer JL, Crockett A, **Abernethy AP**. A community population survey of prevalence and severity of dyspnea in adults. *J Pain Symptom Manage.* Oct 2009;38(4):533-545. 10.1016/j.jpainsymman.2009.01.006

**101. Cherny NI**, **Abernethy AP**, Strasser F, Sapir R, Currow D, Zafar SY. Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review. *J Clin Oncol.* Nov 10 2009;27(32):5476-5486. 10.1200/JCO.2009.21.9592

**102. Abernethy AP**, Uronis HE, Wheeler JL, Currow DC. Management of dyspnea in patients with chronic obstructive pulmonary disease [Review]. *Wien Med Wochenschr.* Dec 2009;159(23-24):583-590. 10.1007/s10354-009-0727-z

**103. O'Connor M**, Davis MP, **Abernethy AP**. Language, discourse and meaning in palliative medicine [Review]. *Progress Palliat Care.* 2010;18(2):1-6.

**104. Abernethy AP**, Clark K, Currow DC. How should we conduct and interpret phase III clinical trials in palliative care? [Letter]. *J Pain Symptom Manage.* Jan 2010;39(1):e6-8. 10.1016/j.jpainsymman.2009.08.003

**105. Hanson LC**, Schenck AP, Rokoske FS, **Abernethy AP**, Kutner JS, Spence C, Person JL. Hospices' preparation and practices for quality measurement. *J Pain Symptom Manage.* Jan 2010;39(1):1-8. 10.1016/j.jpainsymman.2009.09.003

**106. Zafar SY**, Marcello JE, Wheeler JL, Rowe KL, Morse MA, Herndon JE, 2nd, **Abernethy AP**. Treatment-related toxicity and supportive care in metastatic colorectal cancer. *J Support Oncol.* Jan-Feb 2010;8(1):15-20.

**107. Abernethy AP**, Wheeler JL, Zafar SY. Management of gastrointestinal symptoms in advanced cancer patients: the rapid learning cancer clinic model [Review]. *Curr Opin Support Palliat Care.* Mar 2010;4(1):36-45. 10.1097/SPC.0b013e32833575fd

**108. Currow DC**, Smith J, Davidson PM, Newton PJ, Agar MR, **Abernethy AP**. Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. *J Pain Symptom Manage.* Apr 2010;39(4):680-690. 10.1016/j.jpainsymman.2009.09.017

109. Dinan MA, Curtis LH, Hammill BG, Patz EF, Jr., **Abernethy AP**, Shea AM, Schulman KA. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. *JAMA*. Apr 28 2010;303(16):1625-1631. 10.1001/jama.2010.460
110. **Abernethy AP**, Coeytaux RR, Carson K, McCrory DC, Barbour SY, Gradison M, Irvine RJ, Wheeler JL. *Technology Assessment: Report on the evidence regarding off-Label indications for targeted therapies used in cancer treatment*. Rockville, MD: United States Agency for Healthcare Research and Quality; May 2010.  
<http://www.ahrq.gov/clinic/ta/comments/targettherapy/>
111. **Abernethy AP**, Currow DC, Wurzelmann J, Janning SW, Bull J, Norris JF, Baringtang DC, Pierce A, Snidow J. Enhancing enrollment in palliative care trials: key insights from a randomized, placebo-controlled study. *J Support Oncol*. May-Jun 2010;8(3):139-144.
112. **Abernethy AP**, Ahmad A, Zafar SY, Wheeler JL, Reese JB, Lyerly HK. Electronic patient-reported data capture as a foundation of rapid learning cancer care. *Med Care*. Jun 2010;48(6 Suppl):S32-38. 10.1097/MLR.0b013e3181db53a4
113. **Abernethy AP**, Wheeler JL, Currow DC. Common approaches to dyspnoea management in advanced life-limiting illness [Review]. *Curr Opin Support Palliat Care*. Jun 2010;4(2):53-55. 10.1097/SPC.0b013e328338f921
114. Agar M, To T, Plummer J, **Abernethy A**, Currow D. Anti-cholinergic load, health care utilization, and survival in people with advanced cancer: a pilot study. *J Palliat Med*. Jun 2010;13(6):745-752. 10.1089/jpm.2009.0365
115. Aoun S, McConigley R, **Abernethy A**, Currow DC. Caregivers of people with neurodegenerative diseases: profile and unmet needs from a population-based survey in South Australia. *J Palliat Med*. Jun 2010;13(6):653-661. 10.1089/jpm.2009.0318
116. Casadio M, Biasco G, **Abernethy A**, Bonazzi V, Pannuti R, Pannuti F. The National Tumor Association Foundation (ANT): A 30 year old model of home palliative care. *BMC Palliat Care*. Jun 2010;9:12. 10.1186/1472-684X-9-12
117. Currow DC, Agar M, Plummer JL, Blyth FM, **Abernethy AP**. Chronic pain in South Australia - population levels that interfere extremely with activities of daily living. *Aust N Z J Public Health*. Jun 2010;34(3):232-239. 10.1111/j.1753-6405.2010.00519.x
118. Tieman JJ, **Abernethy A**, Currow DC. Not published, not indexed: issues in generating and finding hospice and palliative care literature. *J Palliat Med*. Jun 2010;13(6):669-675. 10.1089/jpm.2009.0273
119. Xue D, **Abernethy AP**. Management of dyspnea in advanced lung cancer: recent data and emerging concepts [Review]. *Curr Opin Support Palliat Care*. Jun 2010;4(2):85-91. 10.1097/SPC.0b013e328339920d
120. **Abernethy AP**, Herndon JE, 2nd, Coan A, Staley T, Wheeler JL, Rowe K, Smith SK, Lyerly HK. Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients. *Support Care Cancer*. Jul 2010;18(7):893-898. 10.1007/s00520-010-0823-z
121. Friedman DR, Coan AD, Smith SK, Herndon JE, 2nd, **Abernethy AP**. Informational needs assessment of non-Hodgkin lymphoma survivors and their physicians [Letter]. *Am J Hematol*. Jul 2010;85(7):528-532. 10.1002/ajh.21725
122. Reese JB, Keefe FJ, Somers TJ, **Abernethy AP**. Coping with sexual concerns after cancer: the use of flexible coping. *Support Care Cancer*. Jul 2010;18(7):785-800. 10.1007/s00520-010-0819-8

- 123.** Berger AM, **Abernethy AP**, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI. Cancer-related fatigue. *J Natl Compr Canc Netw*. Aug 2010;8(8):904-931.
- 124.** Bull J, Zafar SY, Wheeler JL, Harker M, Gblopkor A, Hanson L, Hulihan D, Nugent R, Morris J, **Abernethy AP**. Establishing a regional, multisite database for quality improvement and service planning in community-based palliative care and hospice. *J Palliat Med*. Aug 2010;13(8):1013-1020. 10.1089/jpm.2010.0017
- 125.** Butt Z, Rao AV, Lai JS, **Abernethy AP**, Rosenbloom SK, Cella D. Age-associated differences in fatigue among patients with cancer. *J Pain Symptom Manage*. Aug 2010;40(2):217-223. 10.1016/j.jpainsymman.2009.12.016
- 126.** Leblanc TW, Kutner JS, Ko D, Wheeler JL, Bull J, **Abernethy AP**. Developing the evidence base for palliative care: formation of the palliative care research cooperative and its first trial. *Hosp Pract (Minneap)*. Aug 2010;38(5):137-143. 10.3810/hp.2010.06.320
- 127.** **Abernethy AP**, Currow DC. Need for mechanistically focused research of global systemic interventions in palliative care [Letter]. *J Pain Symptom Manage*. Sep 2010;40(3):e5-8. 10.1016/j.jpainsymman.2010.06.006
- 128.** LeBlanc TW, Wheeler JL, **Abernethy AP**. Research in end-of-life settings: an ethical inquiry [Review]. *J Pain Palliat Care Pharmacother*. Sep 2010;24(3):244-250. 10.3109/15360288.2010.493579
- 129.** Reese JB, Shelby RA, Keefe FJ, Porter LS, **Abernethy AP**. Sexual concerns in cancer patients: a comparison of GI and breast cancer patients. *Support Care Cancer*. Sep 2010;18(9):1179-1189. 10.1007/s00520-009-0738-8
- 130.** Swarm R, **Abernethy AP**, Anghelescu DL, Benedetti C, Blinderman CD, Boston B, Cleeland C, Coyle N, Deleon-Casasola OA, Eilers JG, Ferrell B, Janjan NA, Karver SB, Levy MH, Lynch M, Moryl N, Murphy BA, Nesbit SA, Oakes L, Obbens EA, Paice JA, Rabow MW, Syrjala KL, Urba S, Weinstein SM. Adult cancer pain. *J Natl Compr Canc Netw*. Sep 2010;8(9):1046-1086.
- 131.** **Abernethy AP**, McDonald CF, Frith PA, Clark K, Herndon JE, 2nd, Marcello J, Young IH, Bull J, Wilcock A, Booth S, Wheeler JL, Tulskey JA, Crockett AJ, Currow DC. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. *Lancet*. Sep 4 2010;376(9743):784-793. 10.1016/S0140-6736(10)61115-4
- 132.** **Abernethy AP**, Etheredge LM, Ganz PA, Wallace P, German RR, Neti C, Bach PB, Murphy SB. Rapid-learning system for cancer care. *J Clin Oncol*. Sep 20 2010;28(27):4268-4274. 10.1200/JCO.2010.28.5478
- 133.** **Abernethy AP**, Wheeler JL, Currow DC. Utility and use of palliative care screening tools in routine oncology practice [Review]. *Cancer J*. Sep-Oct 2010;16(5):444-460. 10.1097/PPO.0b013e3181f45df0
- 134.** Zafar SY, Currow DC, Daugherty CK, **Abernethy AP**. Standards for palliative care delivery in oncology settings. *Cancer J*. Sep-Oct 2010;16(5):436-443. 10.1097/PPO.0b13e3181f289f7
- 135.** **Abernethy AP**, Zafar SY, Uronis H, Wheeler JL, Coan A, Rowe K, Shelby RA, Fowler R, Herndon JE, 2nd. Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients. *J Pain Symptom Manage*. Oct 2010;40(4):545-558.

10.1016/j.jpainsymman.2010.01.017

**136.** Burns CM, LeBlanc TW, **Abernethy A**, Currow D. Young caregivers in the end-of-life setting: a population-based profile of an emerging group. *J Palliat Med*. Oct 2010;13(10):1225-1235. 10.1089/jpm.2010.0004

**137.** Currow DC, **Abernethy AP**. Potential opioid-sparing effect of regular benzodiazepines in dyspnea: longer duration of studies needed [Letter]. *J Pain Symptom Manage*. Nov 2010;40(5):e1-2; author reply e2-4. 10.1016/j.jpainsymman.2010.07.002

**138.** Pollak KI, Arnold R, Alexander SC, Jeffreys AS, Olsen MK, **Abernethy AP**, Rodriguez KL, Tulskey JA. Do patient attributes predict oncologist empathic responses and patient perceptions of empathy? *Support Care Cancer*. Nov 2010;18(11):1405-1411. 10.1007/s00520-009-0762-8

**139.** **Abernethy AP**, Aziz NM, Basch E, Bull J, Cleeland CS, Currow DC, Fairclough D, Hanson L, Hauser J, Ko D, Lloyd L, Morrison RS, Otis-Green S, Pantilat S, Portenoy RK, Ritchie C, Rocker G, Wheeler JL, Zafar SY, Kutner JS. A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group. *J Palliat Med*. Dec 2010;13(12):1407-1413. 10.1089/jpm.2010.0261

**140.** Morgan PA, de Oliveira JS, Alexander SC, Pollak KI, Jeffreys AS, Olson MK, Arnold RM, **Abernethy AP**, Rodrigues KL, Tulskey JA. Comparing oncologist, nurse, and physician assistant attitudes toward discussions of negative emotions with patients. *J Physician Assist Educ*. Dec 2010;21(3):13-17.

**141.** Alexander SC, Pollak KI, Morgan PA, Strand J, **Abernethy AP**, Jeffreys AS, Arnold RM, Olsen M, Rodriguez KL, Garrigues SK, Manusov JR, Tulskey JA. How do non-physician clinicians respond to advanced cancer patients' negative expressions of emotions? *Support Care Cancer*. Jan 2011;19(1):155-159. 10.1007/s00520-010-0996-5

**142.** Bowden JA, To TH, **Abernethy AP**, Currow DC. Predictors of chronic breathlessness: a large population study. *BMC Public Health*. Jan 2011;11(1):33. 10.1186/1471-2458-11-33

**143.** Reese JB, Shelby RA, **Abernethy AP**. Sexual concerns in lung cancer patients: an examination of predictors and moderating effects of age and gender. *Support Care Cancer*. Jan 2011;19(1):161-165. 10.1007/s00520-010-1000-0

**144.** Basch E, **Abernethy AP**. Encouraging clinicians to incorporate longitudinal patient-reported symptoms in routine clinical practice [Editorial]. *J Oncol Pract*. Jan 2011;7(1):23-25. 10.1200/JOP.2010.000186

**145.** Burns CM, **Abernethy AP**, Leblanc TW, Currow DC. What is the role of friends when contributing care at the end of life? Findings from an Australian population study. *Psychooncology*. Feb 2011;20(2):203-212. 10.1002/pon.1725

**146.** Jensen SE, Rosenbloom SK, Beaumont JL, **Abernethy A**, Jacobsen PB, Syrjala K, Cella D. A new index of priority symptoms in advanced ovarian cancer. *Gynecol Oncol*. Feb 2011;120(2):214-219. 10.1016/j.ygyno.2010.09.025

**147.** Currow DC, Foley K, Zafar SY, Wheeler JL, **Abernethy AP**. The need for a re-evaluation of best supportive care studies reported to date [Editorial]. *Br J Cancer*. Feb 2011;104(3):390-391. 10.1038/sj.bjc.6606081

**148.** Currow DC, Agar M, **Abernethy AP**. Tackling the challenges of clinical trials in palliative care [Review]. *Pharmaceutical Medicine*. 2011;25(1):7-15. 10.2165/11539790-000000000-00000



149. Xue D, Wheeler JL, **Abernethy AP**. Cultural differences in truth-telling to cancer patients: Chinese and American approaches to the disclosure of 'bad news'. *Progress Palliat Care*. 2011;19(3):125-131. 10.1179/1743291X11Y.0000000004
150. Currow DC, **Abernethy AP**, Bausewein C, Johnson M, Harding R, Higginson I. Measuring the net benefits of hospice and palliative care: a composite measure for multiple audiences-palliative net benefit [Editorial]. *J Palliat Med*. Mar 2011;14(3):264-265. 10.1089/jpm.2011.9722
151. Currow DC, Agar MR, To TH, Rowett D, Greene A, **Abernethy AP**. Adverse events in hospice and palliative care: a pilot study to determine feasibility of collection and baseline rates. *J Palliat Med*. Mar 2011;14(3):309-314. 10.1089/jpm.2010.0392
152. Moroni M, Bolognesi D, Muciarelli PA, **Abernethy AP**, Biasco G. Investment of palliative medicine in bridging the gap with academia: A call to action. *Eur J Cancer*. Mar 2011;47(4):491-495. 10.1016/j.ejca.2010.12.014
153. Cella D, Rosenbloom SK, Beaumont JL, Yount SE, Paul D, Hampton D, **Abernethy AP**, Jacobsen PB, Syrjala K, Von Roenn JH. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. *J Natl Compr Canc Netw*. Mar 1 2011;9(3):268-278.
154. Basch E, **Abernethy AP**. Supporting clinical practice decisions with real-time patient-reported outcomes [Editorial]. *J Clin Oncol*. Mar 10 2011;29(8):954-956. 10.1200/JCO.2010.33.2668
155. **Abernethy AP**, Hesse BW. Guest editors' introduction to the special section on information technology and evidence implementation [Editorial]. *Translational Behavioral Medicine*. 2011;1(1):11-14. 10.1007/s13142-011-0014-6
156. **Abernethy AP**, Wheeler JL. True translational research: bridging the three phases of translation through data and behavior [Editorial]. *Translational Behavioral Medicine*. 2011;1(1):26-30. 10.1007/s13142-010-0013-z
157. **Abernethy AP**, Wheeler JL, Courtney PK, Keefe FJ. Supporting implementation of evidence-based behavioral interventions: the role of data liquidity in facilitating translational behavioral medicine [Review]. *Translational Behavioral Medicine*. 2011;1(1):45-52. 10.1007/s13142-011-0024-4
158. Bruner DW, Hanisch LJ, Reeve BB, Trotti AM, Schrag D, Sit L, Mendoza TR, Minasian L, O'Mara A, Denicoff AM, Rowland JH, Montello M, Geoghegan C, **Abernethy AP**, Clauser SB, Castro K, Mitchell SA, Burke L, Trentacosti AM, Basch E. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *Translational Behavioral Medicine*. 2011;1(1):110-122. DOI: 10.1007/s13142-011-0025-3
159. Currow DC, Burns C, Agar M, Phillips J, McCaffrey N, **Abernethy AP**. Palliative caregivers who would not take on the caring role again. *J Pain Symptom Manage*. Apr 2011;41(4):661-672. 10.1016/j.jpainsymman.2010.06.017
160. Hegarty MM, **Abernethy AP**, Olver I, Currow DC. Former palliative caregivers who identify that additional spiritual support would have been helpful in a population survey. *Palliat Med*. Apr 2011;25(3):266-277. 10.1177/0269216310389225
161. **Abernethy AP**, Wheeler JL, Bull J. Development of a health information technology-based data system in community-based hospice and palliative care. *Am J Prev Med*. May 2011;40(5 Suppl 2):S217-224. 10.1016/j.amepre.2011.01.012

162. Smith SK, Herndon JE, Lysterly HK, Coan A, Wheeler JL, Staley T, **Abernethy AP**. Correlates of quality of life-related outcomes in breast cancer patients participating in the Pathfinders pilot study. *Psychooncology*. May 2011;20(5):559-564. 10.1002/pon.1770
163. Uronis H, McCrory DC, Samsa G, Currow D, **Abernethy A**. Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2011(6):CD006429. 10.1002/14651858.CD006429.pub2
164. **Abernethy AP**. "Learning health care" for patients and populations [Editorial]. *Med J Aust*. Jun 6 2011;194(11):564.
165. **Abernethy AP**, Kassner CT, Whitten E, Bull J, Taylor DH, Jr. Death service ratio: a measure of hospice utilization and cost impact [Letter]. *J Pain Symptom Manage*. Jun 2011;41(6):e5-6. 10.1016/j.jpainsymman.2011.03.004
166. Currow DC, Wheeler JL, **Abernethy AP**. International perspective: Outcomes of palliative oncology [Review]. *Semin Oncol*. Jun 2011;38(3):343-350. 10.1053/j.seminoncol.2011.03.001
167. Currow DC, **Abernethy AP**. Therapeutic nihilism: the next hurdle in improving the treatment of breathlessness [Editorial]. *Curr Opin Support Palliat Care*. Jun 2011;5(2):69-70. 10.1097/SPC.0b013e32834680ea
168. **Abernethy AP**, Kamal AH, Wheeler JL, Cox C. Management of dyspnea within a rapid learning healthcare model [Review]. *Curr Opin Support Palliat Care*. Jun 2011;5(2):101-110. 10.1097/SPC.0b013e32834582b3
169. Hirsch BR, Giffin RB, Esmail LC, Tunis SR, **Abernethy AP**, Murphy SB. Informatics in action: Lessons learned in comparative effectiveness research [Review]. *Cancer J*. Jul-Aug 2011;17(4):235-238. 10.1097/PPO.0b013e31822c3944
170. Basch EM, Reeve BB, Mitchell SA, Clauser SB, Minasian L, Sit L, Chilukuri R, Baumgartner P, Rogak L, Blauel E, **Abernethy AP**, Bruner D. Electronic toxicity monitoring and patient-reported outcomes [Review]. *Cancer J*. Jul-Aug 2011;17(4):231-234. 10.1097/PPO.0b013e31822c28b3
171. **Abernethy AP**, Basch E. Clinical cancer informatics: Creating pathways for personalized medicine and rapid learning cancer care [Editorial]. *Cancer J*. Jul-Aug 2011;17(4):195-196. 10.1097/PPO.0b013e31822c821d
172. Kravchenko J, Akushevich I, Seewaldt VL, **Abernethy AP**, Lysterly HK. Breast cancer as heterogeneous disease: Contributing factors and carcinogenesis mechanisms. *Breast Cancer Res Treat*. Jul 2011;128(2):483-493. 10.1007/s10549-011-1347-z
173. Tcheung WJ, Marcello JE, Puri PK, **Abernethy AP**, Nelson KC. Evaluation of 39 cases of pediatric cutaneous head and neck melanoma. *J Am Acad Dermatol*. Aug 2011;65(2):e37-42. 10.1016/j.jaad.2010.10.003
174. Kamal AH, Currow DC, Ritchie C, Bull J, Wheeler JL, **Abernethy AP**. The value of data collection within a palliative care program [Review]. *Curr Oncol Rep*. Aug 2011;13(4):308-315. 10.1007/s11912-011-0178-8
175. Sampson JH, Herndon JE, 2nd, Friedman AH, **Abernethy AP**. Epidemiology. Data, data everywhere: what could we learn by keeping our eyes open? [Editorial]. *J Neurosurg*. Aug 2011;115(2):256-257; discussion 257-258. 10.3171/2011.1.JNS102066
176. Ginsburg GS, Staples J, **Abernethy AP**. Academic medical centers: Ripe for rapid-learning personalized health care [Review]. *Sci Transl Med*. Sep 21 2011;3(101):101cm127.

10.1126/scitranslmed.3002386

**177.** Currow DC, McDonald C, Oaten S, Kenny B, Allcroft P, Frith P, Briffa M, Johnson MJ, **Abernethy AP**. Once-daily opioids for chronic dyspnea: A dose increment and pharmacovigilance study. *J Pain Symptom Manage*. Sep 2011;42(3):388-399. 10.1016/j.jpainsymman.2010.11.021

**178.** Lysterly HK, **Abernethy AP**, Stockler MR, Koczwara B, Aziz Z, Nair R, Seymour L. Need for global partnership in cancer care: Perceptions of cancer care researchers attending the 2010 Australia and Asia Pacific Clinical Oncology Research Development Workshop. *J Oncol Pract*. 2011;7(5):324-329. doi: 10.1200/JOP.2011.000230

**179.** **Abernethy AP**, Currow DC. Patient self-reporting in palliative care using information technology: Yes, there is hope! [Editorial]. *Palliat Med*. Vol 25. 2011/10/12 ed2011:673-674.

**180.** Kamal AH, Maguire JM, Wheeler JL, Currow DC, **Abernethy AP**. Dyspnea review for the palliative care professional: Assessment, burdens, and etiologies [Review]. *J Palliat Med*. Oct 2011;14(10):1167-1172. 10.1089/jpm.2011.0109

**181.** Kamal AH, Bull J, Stinson C, Blue D, Smith R, Hooper R, Kelly M, Kinsella J, Philbrick M, Gbolkpor A, Wheeler JL, Downey W, **Abernethy AP**. Collecting data on quality is feasible in community-based palliative care. *J Pain Symptom Manage*. Nov 2011;42(5):663-667. 10.1016/j.jpainsymman.2011.07.003

**182.** Tulsky JA, Arnold RM, Alexander SC, Olsen MK, Jeffreys AS, Rodriguez KL, Skinner CS, Farrell D, **Abernethy AP**, Pollak KI. Enhancing communication between oncologists and patients with a computer-based training program: a randomized trial. *Ann Intern Med*. Nov 1 2011;155(9):593-601. 10.1059/0003-4819-155-9-201111010-00007

**183.** Mosca PJ, Blazer DG, 3rd, Wheeler JL, **Abernethy AP**. When a chance to cure is not a chance to cure: A future for palliative surgery? [Editorial]. *Ann Surg Oncol*. Nov 2011;18(12):3235-3239. 10.1245/s10434-011-1787-z

**184.** Currow DC, Farquhar M, Ward AM, Crawford GB, **Abernethy AP**. Caregivers' perceived adequacy of support in end-stage lung disease: results of a population survey. *BMC Pulm Med*. Nov 25 2011;11(1):55. 10.1186/1471-2466-11-55

**185.** **Abernethy AP**, Currow DC. Time for better integration of oncology and palliative care [Editorial]. *J Oncol Pract*. 2011;7(6):346-348. DOI: 10.1200/JOP.2011.000467

**186.** Kamal AH, Bull J, Kavalieratos D, Taylor DH, Downey W, **Abernethy AP**. Palliative care needs of cancer patients living in the community. *J Oncol Pract*. 2011;7(6):382-388. DOI: 10.1200/JOP.2011.000455

**187.** Suh S, Leblanc TW, Shelby RA, Samsa GP, **Abernethy AP**. Longitudinal patient-reported performance status assessment in the cancer clinic is feasible and prognostic. *J Oncol Pract*. 2011;7(6):374-381. DOI: 10.1200/JOP.2011.000434

**188.** LeBlanc TW, **Abernethy AP**. Palliative care and oncology: integration leads to better care [Editorial]. *Oncology (Williston Park)*. Nov 30 2011;25(13):1275.

**189.** Smith SK, Zimmerman S, Williams CS, Benecha H, **Abernethy AP**, Mayer DK, Edwards LJ, Ganz PA. Post-traumatic stress symptoms in long-term non-Hodgkin's lymphoma survivors: Does time heal? *J Clin Oncol*. Dec 1 2011;29(34):4526-4533. 10.1200/JCO.2011.37.2631

**190.** Basch E, **Abernethy AP**, Reeve BB. Assuring the patient centeredness of patient-reported outcomes: Content validity in medical product development and comparative effectiveness research [Editorial]. *Value Health*. Dec 2011;14(8):965-966.

10.1016/j.jval.2011.10.002

**191.** Hendrix CC, Landerman R, **Abernethy AP**. Effects of an individualized caregiver training intervention on self-efficacy of cancer caregivers. *West J Nurs Res*. Sep 26 2011. 10.1177/0193945911420742

**192.** Wood WA, **Abernethy AP**, Giralt SA. Pre-transplant assessments and symptom profiles: Predicting transplant-related toxicity and improving patient-centered outcomes [Review]. *Biol Blood Marrow Transplant*. Oct 17 2011. 10.1016/j.bbmt.2011.10.014

**193.** Shelby-James TM, Hardy J, Agar M, Yates P, Mitchell G, Sanderson C, Luckett T, **Abernethy AP**, Currow DC. Designing and conducting randomized controlled trials in palliative care: A summary of discussions from the 2010 clinical research forum of the Australian Palliative Care Clinical Studies Collaborative. *Palliat Med*. Aug 15 2011. 10.1177/0269216311417036

**194.** Weinstein SM, **Abernethy AP**, Spruill SE, Pike IM, Kelly AT, Jett LG. A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: A placebo-controlled, proof-of-concept trial. *J Pain Symptom Manage*. Oct 7 2011. 10.1016/j.jpainsymman.2011.05.003

**195.** Flynn KE, Reese JB, Jeffery DD, **Abernethy AP**, Lin L, Shelby RA, Porter LS, Dombeck CB, Weinfurt KP. Patient experiences with communication about sex during and after treatment for cancer. *Psychooncology*. Mar 10 2011. 10.1002/pon.1947

**196.** Jones LW, Hornsby WE, Goetzinger A, Forbes LM, Sherrard EL, Quist M, Lane AT, West M, Eves ND, Gradison M, Coan A, Herndon JE, **Abernethy AP**. Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. *Lung Cancer*. Nov 21 2011. 10.1016/j.lungcan.2011.10.009

**197.** Pearce MJ, Coan AD, Herndon JE, 2nd, Koenig HG, **Abernethy AP**. Unmet spiritual care needs impact emotional and spiritual well-being in advanced cancer patients. *Support Care Cancer*. Nov 29 2011. 10.1007/s00520-011-1335-1

**198.** Johnson MJ, **Abernethy AP**, Currow DC. Gaps in the evidence base of opioids for refractory breathlessness. A future work plan? [Review]. *J Pain Symptom Manage*. Mar 2012;43(3):614-624. 10.1016/j.jpainsymman.2011.04.024

**199.** Abernethy, A. P. (2012a). A Balanced Approach to Physician Responsibilities: Oncologists' Duties toward Themselves. *American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting*, e9–e14. [http://doi.org/10.14694/EdBook\\_AM.2012.32.e9](http://doi.org/10.14694/EdBook_AM.2012.32.e9)

**200.** Abernethy, A. P. (2012b). PC-FACS. *Journal of Pain and Symptom Management*, 43(3), 651–662. [http://doi.org/10.1016/S0885-3924\(12\)00044-9](http://doi.org/10.1016/S0885-3924(12)00044-9)

**201.** Abernethy, A. P., & Currow, D. C. (2012, January). Time-limited trials. *JAMA*. United States. <http://doi.org/10.1001/jama.2011.1954>

**202.** Basch, E., Abernethy, A. P., Mullins, C. D., Reeve, B. B., Smith, M. Lou, Coons, S. J., ... Tunis, S. (2012). Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology*, 30(34), 4249–4255. <http://doi.org/10.1200/JCO.2012.42.5967>

**203.** Beasley, G. M., Parsons, C., Broadwater, G., Selim, M. A., Marzban, S., Abernethy, A. P., ... Tyler, D. S. (2012). A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. *Annals of Surgery*, 256(2),

350–356. <http://doi.org/10.1097/SLA.0b013e318256d1f5>

**204.** Bull, J. H., Whitten, E., Morris, J., Hooper, R. N., Wheeler, J. L., Kamal, A., & Abernethy, A. P. (2012). Demonstration of a sustainable community-based model of care across the palliative care continuum. *Journal of Pain and Symptom Management*, 44(6), 797–809. <http://doi.org/10.1016/j.jpainsymman.2011.12.278>

**205.** Butt, Z., Parikh, N. D., Beaumont, J. L., Rosenbloom, S. K., Syrjala, K. L., Abernethy, A. P., ... Cella, D. (2012). Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI). *Cancer*, 118(23), 5997–6004. <http://doi.org/10.1002/cncr.27588>

**206.** Carpenter, W. R., Meyer, A.-M., Abernethy, A. P., Sturmer, T., & Kosorok, M. R. (2012). A framework for understanding cancer comparative effectiveness research data needs. *Journal of Clinical Epidemiology*, 65(11), 1150–1158. <http://doi.org/10.1016/j.jclinepi.2012.06.005>

**207.** Currow, D. C., & Abernethy, A. P. (2012). The ultimate personalised medicine. *International Journal of Clinical Practice*, 66(9), 824–826. <http://doi.org/10.1111/j.1742-1241.2012.02980.x>

**208.** Currow, D. C., & Abernethy, A. P. (2012, June). Breathlessness in an age of noncommunicable diseases. *Current Opinion in Supportive and Palliative Care*. United States. <http://doi.org/10.1097/SPC.0b013e3283537d26>

**209.** Currow, D. C., Abernethy, A. P., & Johnson, M. J. (2012, November). Activity as a measure of symptom control. *Journal of Pain and Symptom Management*. United States. <http://doi.org/10.1016/j.jpainsymman.2012.07.005>

**210.** Currow, D. C., Bruner, D. W., & Abernethy, A. P. (2012, December). Editorial: death to the fiefdoms. *Current Opinion in Supportive and Palliative Care*. United States. <http://doi.org/10.1097/SPC.0b013e32835a589a>

**211.** Currow, D. C., Plummer, J. L., Kutner, J. S., Samsa, G. P., & Abernethy, A. P. (2012). Analyzing phase III studies in hospice/palliative care: a solution that sits between intention-to-treat and per protocol analyses: the palliative-modified ITT analysis. *Journal of Pain and Symptom Management*, 44(4), 595–603. <http://doi.org/10.1016/j.jpainsymman.2011.10.028>

**212.** Currow, D. C., Rowett, D., Doogue, M., To, T. H. M., & Abernethy, A. P. (2012). An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice. *Journal of Palliative Medicine*, 15(3), 282–286. <http://doi.org/10.1089/jpm.2012.9605>

**213.** Currow, D. C., Tieman, J. J., Greene, A., Zafar, S. Y., Wheeler, J. L., & Abernethy, A. P. (2012). Refining a checklist for reporting patient populations and service characteristics in hospice and palliative care research. *Journal of Pain and Symptom Management*, 43(5), 902–910. <http://doi.org/10.1016/j.jpainsymman.2011.05.015>

**214.** Dev, S., Abernethy, A. P., Rogers, J. G., & O'Connor, C. M. (2012). Preferences of people with advanced heart failure—a structured narrative literature review to inform decision making in the palliative care setting. *American Heart Journal*, 164(3), 313–319.e5. <http://doi.org/10.1016/j.ahj.2012.05.023>

**215.** Dinan, M. A., Curtis, L. H., Carpenter, W. R., Biddle, A. K., Abernethy, A. P., Patz, E. F. J., ... Weinberger, M. (2012). Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998–2003. *Journal of Clinical Oncology: Official Journal of the American Society*

of *Clinical Oncology*, 30(22), 2725–2730. <http://doi.org/10.1200/JCO.2011.40.4392>

**216.** Flynn, K. E., Reese, J. B., Jeffery, D. D., Abernethy, A. P., Lin, L., Shelby, R. A., ... Weinfurt, K. P. (2012). Patient experiences with communication about sex during and after treatment for cancer. *Psycho-Oncology*, 21(6), 594–601. <http://doi.org/10.1002/pon.1947>

**217.** Hirsch, B. R., & Abernethy, A. P. (2012). Structured decision-making: using personalized medicine to improve the value of cancer care. *Journal of Personalized Medicine*, 3(1), 1–13. <http://doi.org/10.3390/jpm3010001>

**218.** Irwin, B., Hirsch, B. R., Samsa, G. P., & Abernethy, A. P. (2012). Conflict of interest disclosure in off-label oncology clinical trials. *Journal of Oncology Practice / American Society of Clinical Oncology*, 8(5), 298–302. <http://doi.org/10.1200/JOP.2011.000523>

**219.** Johnson, M. J., Abernethy, A. P., & Currow, D. C. (2012). Gaps in the evidence base of opioids for refractory breathlessness. A future work plan? *Journal of Pain and Symptom Management*, 43(3), 614–624. <http://doi.org/10.1016/j.jpainsymman.2011.04.024>

**220.** Johnson, M. J., Bowden, J. A., Abernethy, A. P., & Currow, D. C. (2012). To what causes do people attribute their chronic breathlessness? A population survey. *Journal of Palliative Medicine*, 15(7), 744–750. <http://doi.org/10.1089/jpm.2011.0430>

**221.** Jones, L. W., Hornsby, W. E., Goetzinger, A., Forbes, L. M., Sherrard, E. L., Quist, M., ... Abernethy, A. P. (2012). Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. *Lung Cancer (Amsterdam, Netherlands)*, 76(2), 248–252. <http://doi.org/10.1016/j.lungcan.2011.10.009>

**222.** Kamal, A. H., Maguire, J. M., Wheeler, J. L., Currow, D. C., & Abernethy, A. P. (2012). Dyspnea review for the palliative care professional: treatment goals and therapeutic options. *Journal of Palliative Medicine*, 15(1), 106–114. <http://doi.org/10.1089/jpm.2011.0110>

**223.** Kamal, A. H., Miriovsky, B. J., Currow, D. C., & Abernethy, A. P. (2012). Improving the management of dyspnea in the community using rapid learning approaches. *Chronic Respiratory Disease*, 9(1), 51–61. <http://doi.org/10.1177/1479972311433576>

**224.** Kamal, A. H., Swetz, K. M., Dy, S., Tien, A. Y., Temel, J. S., & Abernethy, A. P. (2012). Integrating technology into palliative care research. *Current Opinion in Supportive and Palliative Care*, 6(4), 525–532. <http://doi.org/10.1097/SPC.0b013e32835998c6>

**225.** Kravchenko, J., Akushevich, I., Abernethy, A. P., & Lyster, H. K. (2012). Evaluating the number of stages in development of squamous cell and adenocarcinomas across cancer sites using human population-based cancer modeling. *PloS One*, 7(5), e37430. <http://doi.org/10.1371/journal.pone.0037430>

**226.** LeBlanc, T. W., Abernethy, A. P., Currow, D. C., & Kutner, J. S. (2012). Considerations in reporting palliative care clinical trials: standardizing information reported and authorship practices. *Current Opinion in Supportive and Palliative Care*, 6(4), 494–499. <http://doi.org/10.1097/SPC.0b013e3283597259>

**227.** Lodato, J. E., Aziz, N., Bennett, R. E., Abernethy, A. P., & Kutner, J. S. (2012). Achieving palliative care research efficiency through defining and benchmarking performance metrics. *Current Opinion in Supportive and Palliative Care*, 6(4), 533–542. <http://doi.org/10.1097/SPC.0b013e32835a7cb4>

**228.** Meyer, A.-M., Carpenter, W. R., Abernethy, A. P., Sturmer, T., & Kosorok, M. R. (2012). Data for cancer comparative effectiveness research: past, present, and future potential. *Cancer*, 118(21), 5186–5197. <http://doi.org/10.1002/cncr.27552>

- 229.** Miriovsky, B. J., Shulman, L. N., & Abernethy, A. P. (2012). Importance of health information technology, electronic health records, and continuously aggregating data to comparative effectiveness research and learning health care. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology*, 30(34), 4243–4248. <http://doi.org/10.1200/JCO.2012.42.8011>
- 230.** Moy, B., Abernethy, A. P., & Peppercorn, J. M. (2012). Core elements of the patient protection and affordable care act and their relevance to the delivery of high-quality cancer care. *American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting*, e4–8. [http://doi.org/10.14694/EdBook\\_AM.2012.32.e4](http://doi.org/10.14694/EdBook_AM.2012.32.e4)
- 231.** Mullins, C. D., Montgomery, R., Abernethy, A. P., Hussain, A., Pearson, S. D., & Tunis, S. (2012). Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology*, 30(6), 661–666. <http://doi.org/10.1200/JCO.2011.35.5198>
- 232.** Pearce, M. J., Coan, A. D., Herndon, J. E. 2nd, Koenig, H. G., & Abernethy, A. P. (2012). Unmet spiritual care needs impact emotional and spiritual well-being in advanced cancer patients. *Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer*, 20(10), 2269–2276. <http://doi.org/10.1007/s00520-011-1335-1>
- 233.** Rangwala, F., Zafar, S. Y., & Abernethy, A. P. (2012). Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach. *Current Opinion in Supportive and Palliative Care*, 6(1), 69–76. <http://doi.org/10.1097/SPC.0b013e32834f689d>
- 234.** Ribas, A., Chesney, J. A., Gordon, M. S., Abernethy, A. P., Logan, T. F., Lawson, D. H., ... Gonzalez, R. (2012). Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. *Journal of Translational Medicine*, 10, 236. <http://doi.org/10.1186/1479-5876-10-236>
- 235.** Salama, A. K. S., Rosa, N. de, Scheri, R. P., Herndon, J. E., Tyler, D. S., Marcello, J., ... Abernethy, A. P. (2012). The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost. *Cancer Investigation*, 30(9), 637–641. <http://doi.org/10.3109/07357907.2012.726387>
- 236.** Shelby-James, T. M., Hardy, J., Agar, M., Yates, P., Mitchell, G., Sanderson, C., ... Currow, D. C. (2012). Designing and conducting randomized controlled trials in palliative care: A summary of discussions from the 2010 clinical research forum of the Australian Palliative Care Clinical Studies Collaborative. *Palliative Medicine*, 26(8), 1042–1047. <http://doi.org/10.1177/0269216311417036>
- 237.** Smith, T. J., Temin, S., Alesi, E. R., Abernethy, A. P., Balboni, T. A., Basch, E. M., ... Von Roenn, J. H. (2012). American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology*, 30(8), 880–887. <http://doi.org/10.1200/JCO.2011.38.5161>
- 238.** Tcheung, W. J., Selim, M. A., Herndon, J. E. 2nd, Abernethy, A. P., & Nelson, K. C. (2012). Clinicopathologic study of 85 cases of melanoma of the female genitalia. *Journal of the American Academy of Dermatology*, 67(4), 598–605. <http://doi.org/10.1016/j.jaad.2011.11.921>
- 239.** Uronis, H. E., Shelby, R. A., Currow, D. C., Ahmedzai, S. H., Bosworth, H. B., Coan, A., & Abernethy, A. P. (2012). Assessment of the psychometric properties of an English version of the cancer dyspnea scale in people with advanced lung cancer. *Journal of Pain and Symptom*

*Management*, 44(5), 741–749. <http://doi.org/10.1016/j.jpainsymman.2011.10.027>

**240.** Weinstein, S. M., Abernethy, A. P., Spruill, S. E., Pike, I. M., True Kelly, A., & Jett, L. G. (2012). A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial. *Journal of Pain and Symptom Management*, 43(4), 679–693. <http://doi.org/10.1016/j.jpainsymman.2011.05.003>

**241.** Wheeler, J. L., Greene, A., Tieman, J. J., Abernethy, A. P., & Currow, D. C. (2012). Key characteristics of palliative care studies reported in the specialized literature. *Journal of Pain and Symptom Management*, 43(6), 987–992. <http://doi.org/10.1016/j.jpainsymman.2011.07.012>

**242.** Wood, W. A., Abernethy, A. P., & Giralt, S. A. (2012). Pretransplantation assessments and symptom profiles: predicting transplantation-related toxicity and improving patient-centered outcomes. *Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation*, 18(4), 497–504. <http://doi.org/10.1016/j.bbmt.2011.10.014>

**243.** Yount, S., Beaumont, J., Rosenbloom, S., Cella, D., Patel, J., Hensing, T., ... Abernethy, A. P. (2012). A brief symptom index for advanced lung cancer. *Clinical Lung Cancer*, 13(1), 14–23. <http://doi.org/10.1016/j.dlc.2011.03.033>

**244.** Zafar, S. Y., Currow, D. C., Cherny, N., Strasser, F., Fowler, R., & Abernethy, A. P. (2012). Consensus-based standards for best supportive care in clinical trials in advanced cancer. *The Lancet. Oncology*, 13(2), e77–82. [http://doi.org/10.1016/S1470-2045\(11\)70215-7](http://doi.org/10.1016/S1470-2045(11)70215-7)

**245.** Abernethy, A. P., Bull, J., Whitten, E., Shelby, R., Wheeler, J. L., & Taylor, D. H. J. (2013). Targeted investment improves access to hospice and palliative care. *Journal of Pain and Symptom Management*, 46(5), 629–639. <http://doi.org/10.1016/j.jpainsymman.2012.12.012>

**246.** Abernethy, A. P., Currow, D. C., Shelby-James, T., Rowett, D., May, F., Samsa, G. P., ... Phillips, P. A. (2013). Delivery strategies to optimize resource utilization and performance status for patients with advanced life-limiting illness: results from the “palliative care trial” [ISRCTN 81117481]. *Journal of Pain and Symptom Management*, 45(3), 488–505. <http://doi.org/10.1016/j.jpainsymman.2012.02.024>

**247.** Abernethy, A., Ruiz-Rodriguez, E., & Krasuski, R. A. (2013). Migraine headaches following mitral valvuloplasty: Koch’s postulates finally satisfied? *The Journal of Invasive Cardiology*, 25(6), E120–3.

**248.** Allcroft, P., Margitanovic, V., Greene, A., Agar, M. R., Clark, K., Abernethy, A. P., & Currow, D. C. (2013). The role of benzodiazepines in breathlessness: a single site, open label pilot of sustained release morphine together with clonazepam. *Journal of Palliative Medicine*, 16(7), 741–744. <http://doi.org/10.1089/jpm.2012.0505>

**249.** Breaden, K., Phillips, J., Agar, M., Grbich, C., Abernethy, A. P., & Currow, D. C. (2013). The clinical and social dimensions of prescribing palliative home oxygen for refractory dyspnea. *Journal of Palliative Medicine*, 16(3), 268–273. <http://doi.org/10.1089/jpm.2012.0102>

**250.** Burns, C. M., Abernethy, A. P., Dal Grande, E., & Currow, D. C. (2013). Uncovering an invisible network of direct caregivers at the end of life: a population study. *Palliative Medicine*, 27(7), 608–615. <http://doi.org/10.1177/0269216313483664>

**251.** Currow, D. C., & Abernethy, A. P. (2013, June). Five years’ time and the next five things for the list of choosing wisely. *Journal of Palliative Medicine*. United States. <http://doi.org/10.1089/jpm.2013.9506>

**252.** Currow, D. C., Agar, M., & Abernethy, A. P. (2013, February). Hospital can be the actively chosen place for death. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology*. United States. <http://doi.org/10.1200/JCO.2012.46.2556>



- 253.** Currow, D. C., Clark, K., Mitchell, G. K., Johnson, M. J., & Abernethy, A. P. (2013). Prospectively collected characteristics of adult patients, their consultations and outcomes as they report breathlessness when presenting to general practice in Australia. *PloS One*, 8(9), e74814. <http://doi.org/10.1371/journal.pone.0074814>
- 254.** Currow, D. C., Quinn, S., Greene, A., Bull, J., Johnson, M. J., & Abernethy, A. P. (2013). The longitudinal pattern of response when morphine is used to treat chronic refractory dyspnea. *Journal of Palliative Medicine*, 16(8), 881–886. <http://doi.org/10.1089/jpm.2012.0591>
- 255.** Currow, D., Johnson, M., White, P., & Abernethy, A. (2013). Evidence-based intervention for chronic refractory breathlessness: practical therapies that make a difference. *The British Journal of General Practice : The Journal of the Royal College of General Practitioners*, 63(616), 609–610. <http://doi.org/10.3399/bjgp13X674611>
- 256.** Davidson, P. M., Abernethy, A. P., Newton, P. J., Clark, K., & Currow, D. C. (2013). The caregiving perspective in heart failure: a population based study. *BMC Health Services Research*, 13, 342. <http://doi.org/10.1186/1472-6963-13-342>
- 257.** Dinan, M. A., Carpenter, W. R., Patz, E. F. J., Abernethy, A. P., Biddle, A. K., Schulman, K. A., & Curtis, L. H. (2013, February). Reply to M.S. Hofman et al. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology*. United States.
- 258.** Dinan, M. A., Curtis, L. H., Carpenter, W. R., Biddle, A. K., Abernethy, A. P., Patz, E. F. J., ... Weinberger, M. (2013). Variations in use of PET among Medicare beneficiaries with non-small cell lung cancer, 1998-2007. *Radiology*, 267(3), 807–817. <http://doi.org/10.1148/radiol.12120174>
- 259.** Harrison, M. R., George, D. J., Walker, M. S., Chen, C., Korytowsky, B., Kirkendall, D. T., ... Abernethy, A. P. (2013). “Real world” treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy. *Clinical Genitourinary Cancer*, 11(4), 441–450. <http://doi.org/10.1016/j.clgc.2013.05.002>
- 260.** Havrilesky, L. J., & Abernethy, A. P. (2013). Quality of life in ICON7: need for patients’ perspectives. *The Lancet. Oncology*, 14(3), 183–185. [http://doi.org/10.1016/S1470-2045\(12\)70590-9](http://doi.org/10.1016/S1470-2045(12)70590-9)
- 261.** Hendrix, C. C., Landerman, R., & Abernethy, A. P. (2013). Effects of an individualized caregiver training intervention on self-efficacy of cancer caregivers. *Western Journal of Nursing Research*, 35(5), 590–610. <http://doi.org/10.1177/0193945911420742>
- 262.** Hirsch, B. R., & Abernethy, A. P. (2013). Incorporating the patient’s voice in the continuum of care. *Journal of the National Comprehensive Cancer Network : JNCCN*, 11(1), 116–118.
- 263.** Hirsch, B. R., Califf, R. M., Cheng, S. K., Tasneem, A., Horton, J., Chiswell, K., ... Abernethy, A. P. (2013). Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. *JAMA Internal Medicine*, 173(11), 972–979. <http://doi.org/10.1001/jamainternmed.2013.627>
- 264.** Hlubocky, F. J., Webster, K., Beaumont, J., Cashy, J., Paul, D., Abernethy, A., ... Cella, D. (2013). A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Lymphoma Symptom Index. *Leukemia & Lymphoma*, 54(9), 1942–1946. <http://doi.org/10.3109/10428194.2012.762977>
- 265.** Howie, L. J., Hirsch, B. R., & Abernethy, A. P. (2013). A comparison of FDA and EMA drug approval: implications for drug development and cost of care. *Oncology (Williston Park)*,

N. Y.), 27(12), 1195, 1198–1200, 1202 passim.

**266.** Jaggi, R., Chiang, A., Polite, B. N., Medeiros, B. C., McNiff, K., Abernethy, A. P., ... Loehrer, P. J. S. (2013). Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomes. *Journal of Oncology Practice / American Society of Clinical Oncology*, 9(6), e290–7. <http://doi.org/10.1200/JOP.2012.000823>

**267.** Jensen, S. E., Beaumont, J. L., Jacobsen, P. B., Abernethy, A., Syrjala, K. L., & Cella, D. (2013). Measuring priority symptoms in advanced bladder cancer: development and initial validation of a brief symptom index. *The Journal of Supportive Oncology*, 11(2), 86–93. <http://doi.org/10.1016/j.suponc.2012.07.002>

**268.** Johnson, M. J., Abernethy, A. P., & Currow, D. C. (2013). The evidence base for oxygen for chronic refractory breathlessness: issues, gaps, and a future work plan. *Journal of Pain and Symptom Management*, 45(4), 763–775. <http://doi.org/10.1016/j.jpainsymman.2012.03.017>

**269.** Johnson, M. J., Bland, J. M., Oxberry, S. G., Abernethy, A. P., & Currow, D. C. (2013a). Clinically important differences in the intensity of chronic refractory breathlessness. *Journal of Pain and Symptom Management*, 46(6), 957–963. <http://doi.org/10.1016/j.jpainsymman.2013.01.011>

**270.** Johnson, M. J., Bland, J. M., Oxberry, S. G., Abernethy, A. P., & Currow, D. C. (2013b). Opioids for chronic refractory breathlessness: patient predictors of beneficial response. *The European Respiratory Journal*, 42(3), 758–766. <http://doi.org/10.1183/09031936.00139812>

**271.** Kamal, A. H., Bull, J., Stinson, C. S., Blue, D. L., & Abernethy, A. P. (2013). Conformance with supportive care quality measures is associated with better quality of life in patients with cancer receiving palliative care. *Journal of Oncology Practice / American Society of Clinical Oncology*, 9(3), e73–6. <http://doi.org/10.1200/JOP.2013.000948>

**272.** Kamal, A. H., Currow, D. C., Ritchie, C. S., Bull, J., & Abernethy, A. P. (2013). Community-based palliative care: the natural evolution for palliative care delivery in the U.S. *Journal of Pain and Symptom Management*, 46(2), 254–264. <http://doi.org/10.1016/j.jpainsymman.2012.07.018>

**273.** Kravchenko, J., Abernethy, A. P., Fawzy, M., & Lyerly, H. K. (2013). Minimization of heatwave morbidity and mortality. *American Journal of Preventive Medicine*, 44(3), 274–282. <http://doi.org/10.1016/j.amepre.2012.11.015>

**274.** Kumar, S., Nilsen, W. J., Abernethy, A., Atienza, A., Patrick, K., Pavel, M., ... Swendeman, D. (2013). Mobile health technology evaluation: the mHealth evidence workshop. *American Journal of Preventive Medicine*, 45(2), 228–236. <http://doi.org/10.1016/j.amepre.2013.03.017>

**275.** Leblanc, T. W., & Abernethy, A. P. (2013). Defining quality, disseminating evidence, and enforcing guidelines for cancer treatment. *The Virtual Mentor : VM*, 15(8), 713–717. <http://doi.org/10.1001/virtualmentor.2013.15.8.oped1-1308>

**276.** LeBlanc, T. W., & Abernethy, A. P. (2013, June). Quality of life in higher resolution: the next generation of comparative effectiveness research in malignant hematology. *Haematologica*. Italy. <http://doi.org/10.3324/haematol.2013.085787>

**277.** LeBlanc, T. W., Kutner, J. S., Ritchie, C. S., & Abernethy, A. P. (2013, July). Discontinuation of statins in routine care settings. *Annals of Internal Medicine*. United States. <http://doi.org/10.7326/0003-4819-159-1-201307020-00021>

**278.** LeBlanc, T. W., Lodato, J. E., Currow, D. C., & Abernethy, A. P. (2013). Overcoming recruitment challenges in palliative care clinical trials. *Journal of Oncology Practice / American*

*Society of Clinical Oncology*, 9(6), 277–282. <http://doi.org/10.1200/JOP.2013.000996>

**279.** LeBlanc, T. W., Shulman, L. N., Yu, P. P., Hirsch, B. R., & Abernethy, A. P. (2013). The ethics of health information technology in oncology: emerging issues from both local and global perspectives. *American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting*, 136–142.

[http://doi.org/10.1200/EdBook\\_AM.2013.33.136](http://doi.org/10.1200/EdBook_AM.2013.33.136)

**280.** Lopez-Acevedo, M., Havrilesky, L. J., Broadwater, G., Kamal, A. H., Abernethy, A. P., Berchuck, A., ... Lee, P. S. (2013). Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer. *Gynecologic Oncology*, 130(1), 156–161.

<http://doi.org/10.1016/j.ygyno.2013.04.010>

**281.** Ordonana, J. R., Bartels, M., Boomsma, D. I., Cella, D., Mosing, M., Oliveira, J. R., ... Sprangers, M. A. G. (2013). Biological pathways and genetic mechanisms involved in social functioning. *Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation*, 22(6), 1189–1200. <http://doi.org/10.1007/s11136-012-0277-5>

**282.** Pearman, T. P., Beaumont, J. L., Paul, D., Abernethy, A. P., Jacobsen, P. B., Syrjala, K. L., ... Cella, D. (2013). Evaluation of treatment- and disease-related symptoms in advanced head and neck cancer: validation of the national comprehensive cancer network-functional assessment of cancer therapy-head and neck cancer symptom index-22 (NFHNSI-22). *Journal of Pain and Symptom Management*, 46(1), 113–120.

<http://doi.org/10.1016/j.jpainsymman.2012.06.004>

**283.** Quill, T. E., & Abernethy, A. P. (2013). Generalist plus specialist palliative care--creating a more sustainable model. *The New England Journal of Medicine*, 368(13), 1173–1175.

<http://doi.org/10.1056/NEJMp1215620>

**284.** Riley, W. T., Glasgow, R. E., Etheredge, L., & Abernethy, A. P. (2013). Rapid, responsive, relevant (R3) research: a call for a rapid learning health research enterprise. *Clinical and Translational Medicine*, 2(1), 10. <http://doi.org/10.1186/2001-1326-2-10>

**285.** Ritchie, C. S., Currow, D. C., Abernethy, A. P., & Kutner, J. S. (2013, March). Multisite studies offer a solution to recruitment challenges in palliative care studies. *Journal of Palliative Medicine*. United States. <http://doi.org/10.1089/jpm.2012.0480>

**286.** Rothrock, N. E., Jensen, S. E., Beaumont, J. L., Abernethy, A. P., Jacobsen, P. B., Syrjala, K., & Cella, D. (2013). Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer. *Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research*, 16(5), 789–796.

<http://doi.org/10.1016/j.jval.2013.04.015>

**287.** Salama, A. K. S., de Rosa, N., Scheri, R. P., Pruitt, S. K., Herndon, J. E. 2nd, Marcello, J., ... Abernethy, A. P. (2013). Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy. *PloS One*, 8(3), e57665. <http://doi.org/10.1371/journal.pone.0057665>

**288.** Shih, Y.-C. T., Ganz, P. A., Aberle, D., Abernethy, A., Bekelman, J., Brawley, O., ... Schnipper, L. (2013). Delivering high-quality and affordable care throughout the cancer care continuum. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology*, 31(32), 4151–4157. <http://doi.org/10.1200/JCO.2013.51.0651>

**289.** Smith, S. K., Mayer, D. K., Zimmerman, S., Williams, C. S., Benecha, H., Ganz, P. A., ... Abernethy, A. P. (2013). Quality of life among long-term survivors of non-Hodgkin lymphoma: a follow-up study. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical*

*Oncology*, 31(2), 272–279. <http://doi.org/10.1200/JCO.2011.40.6249>

**290.** Swarm, R. A., Abernethy, A. P., Anghelescu, D. L., Benedetti, C., Buga, S., Cleeland, C., ... Kumar, R. (2013). Adult cancer pain. *Journal of the National Comprehensive Cancer Network : JNCCN*, 11(8), 992–1022.

**291.** Taylor, D. H. J., Bull, J., Zhong, X., Samsa, G., & Abernethy, A. P. (2013). The effect of palliative care on patient functioning. *Journal of Palliative Medicine*, 16(10), 1227–1231. <http://doi.org/10.1089/jpm.2013.0040>

**292.** To, T. H. M., Agar, M., Shelby-James, T., Abernethy, A. P., Doogue, M., Rowett, D., ... Currow, D. C. (2013). Off-label prescribing in palliative care - a cross-sectional national survey of palliative medicine doctors. *Palliative Medicine*, 27(4), 320–328. <http://doi.org/10.1177/0269216312464263>

**293.** Ubel, P. A., Abernethy, A. P., & Zafar, S. Y. (2013). Full disclosure—out-of-pocket costs as side effects. *The New England Journal of Medicine*, 369(16), 1484–1486. <http://doi.org/10.1056/NEJMp1306826>

**294.** Wiseman, R., Rowett, D., Allcroft, P., Abernethy, A., & Currow, D. C. (2013). Chronic refractory dyspnoea—evidence based management. *Australian Family Physician*, 42(3), 137–140.

**295.** Wood, W. A., Deal, A. M., Abernethy, A., Basch, E., Battaglini, C., Kim, Y. H., ... Reeve, B. B. (2013). Feasibility of frequent patient-reported outcome surveillance in patients undergoing hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation*, 19(3), 450–459. <http://doi.org/10.1016/j.bbmt.2012.11.014>

**296.** Wood, W. A., Deal, A. M., Reeve, B. B., Abernethy, A. P., Basch, E., Mitchell, S. A., ... Battaglini, C. (2013). Cardiopulmonary fitness in patients undergoing hematopoietic SCT: a pilot study. *Bone Marrow Transplantation*, 48(10), 1342–1349. <http://doi.org/10.1038/bmt.2013.58>

**297.** Zafar, S. Y., & Abernethy, A. P. (2013a). Financial toxicity, Part I: a new name for a growing problem. *Oncology (Williston Park, N. Y.)*, 27(2), 80–81,149.

**298.** Zafar, S. Y., & Abernethy, A. P. (2013b). Financial toxicity, Part II: how can we help with the burden of treatment-related costs? *Oncology (Williston Park, N. Y.)*, 27(4), 253–254,256.

**299.** Zafar, S. Y., Peppercorn, J. M., Schrag, D., Taylor, D. H., Goetzinger, A. M., Zhong, X., & Abernethy, A. P. (2013). The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. *The Oncologist*, 18(4), 381–390. <http://doi.org/10.1634/theoncologist.2012-0279>

**300.** Zullig, L. L., Muiruri, C., Abernethy, A., Weiner, B. J., Bartlett, J., Oneko, O., & Zafar, S. Y. (2013). Cancer registration needs assessment at a tertiary medical centre in Kilimanjaro, Tanzania. *World Health & Population*, 14(2), 12–23.

**301.** Abernethy, A. (2014). Changing the conversation about palliative care. *Modern Healthcare*, 44(14), 26.

**302.** Abernethy, A., Abrahams, E., Barker, A., Buetow, K., Burkholder, R., Dalton, W. S., ... van't Veer, L. (2014). Turning the tide against cancer through sustained medical innovation: the pathway to progress. *Clinical Cancer Research : An Official Journal of the American Association for Cancer Research*, 20(5), 1081–1086. <http://doi.org/10.1158/1078-0432.CCR-13-3430>

**303.** Abernethy, A. P. (2014). Demonstrating the learning health system through practical use cases. *Pediatrics*, 134(1), 171–172. <http://doi.org/10.1542/peds.2014-1182>

- 304.** Abernethy, A. P., Capell, W. H., Aziz, N. M., Ritchie, C., Prince-Paul, M., Bennett, R. E., & Kutner, J. S. (2014). Ethical conduct of palliative care research: enhancing communication between investigators and institutional review boards. *Journal of Pain and Symptom Management*, 48(6), 1211–1221. <http://doi.org/10.1016/j.jpainsymman.2014.05.005>
- 305.** Abernethy, A. P., & Grubbs, S. S. (2014). Managing cumulative expectations in oncology: challenges and potential solutions. *American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting*, e140–4. [http://doi.org/10.14694/EdBook\\_AM.2014.34.e140](http://doi.org/10.14694/EdBook_AM.2014.34.e140)
- 306.** Atisha, D. M., Locklear, T. D., Rogers, U. A., Rushing, C. N., Samsa, G. P., & Abernethy, A. P. (2014, April). Partnering with engaged patients accelerates research. *Journal of Surgical Oncology*. United States. <http://doi.org/10.1002/jso.23515>
- 307.** Bartley, E. J., Edmond, S. N., Wren, A. A., Somers, T. J., Teo, I., Zhou, S., ... Shelby, R. A. (2014). Holding back moderates the association between health symptoms and social well-being in patients undergoing hematopoietic stem cell transplantation. *Journal of Pain and Symptom Management*, 48(3), 374–384. <http://doi.org/10.1016/j.jpainsymman.2013.09.019>
- 308.** Basch, E., Reeve, B. B., Mitchell, S. A., Clauser, S. B., Minasian, L. M., Dueck, A. C., ... Schrag, D. (2014). Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). *Journal of the National Cancer Institute*, 106(9). <http://doi.org/10.1093/jnci/dju244>
- 309.** Bestvina, C. M., Zullig, L. L., Rushing, C., Chino, F., Samsa, G. P., Altomare, I., ... Zafar, S. Y. (2014). Patient-oncologist cost communication, financial distress, and medication adherence. *Journal of Oncology Practice / American Society of Clinical Oncology*, 10(3), 162–167. <http://doi.org/10.1200/JOP.2014.001406>
- 310.** Bull, J. H., & Abernethy, A. P. (2014). Expanding use of palliative care in the oncology setting. *North Carolina Medical Journal*, 75(4), 274–278.
- 311.** Chino, F., Peppercorn, J., Taylor, D. H. J., Lu, Y., Samsa, G., Abernethy, A. P., & Zafar, S. Y. (2014). Self-reported financial burden and satisfaction with care among patients with cancer. *The Oncologist*, 19(4), 414–420. <http://doi.org/10.1634/theoncologist.2013-0374>
- 312.** Cox, C. E., White, D. B., & Abernethy, A. P. (2014). A universal decision support system. Addressing the decision-making needs of patients, families, and clinicians in the setting of critical illness. *American Journal of Respiratory and Critical Care Medicine*, 190(4), 366–373. <http://doi.org/10.1164/rccm.201404-0728CP>
- 313.** Currow, D. C., & Abernethy, A. P. (2014a). Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. *Future Oncology (London, England)*, 10(5), 789–802. <http://doi.org/10.2217/fon.14.14>
- 314.** Currow, D. C., & Abernethy, A. P. (2014b). Lessons from the Liverpool Care Pathway--evidence is key. *Lancet (London, England)*, 383(9913), 192–193. [http://doi.org/10.1016/S0140-6736\(13\)62039-5](http://doi.org/10.1016/S0140-6736(13)62039-5)
- 315.** Currow, D. C., & Abernethy, A. P. (2014c, September). The science of breathlessness: "... as we come onto the home straight, Science is catching Clinical Practice. Just two lengths between them". *Current Opinion in Supportive and Palliative Care*. United States. <http://doi.org/10.1097/SPC.0000000000000067>
- 316.** Currow, D. C., Abernethy, A. P., & Ko, D. N. (2014). The active identification and management of chronic refractory breathlessness is a human right. *Thorax*, 69(4), 393–394. <http://doi.org/10.1136/thoraxjnl-2013-204701>

- 317.** Currow, D. C., Ekstrom, M., & Abernethy, A. P. (2014). Opioids for chronic refractory breathlessness: right patient, right route? *Drugs*, 74(1), 1–6. <http://doi.org/10.1007/s40265-013-0162-8>
- 318.** Danis, M., Abernethy, A. P., Zafar, S. Y., Samsa, G. P., Wolf, S. P., Howie, L., & Taylor, D. H. J. (2014). A decision exercise to engage cancer patients and families in deliberation about Medicare coverage for advanced cancer care. *BMC Health Services Research*, 14, 315. <http://doi.org/10.1186/1472-6963-14-315>
- 319.** Dinan, M. A., Curtis, L. H., Carpenter, W. R., Biddle, A. K., Abernethy, A. P., Patz, E. F. J., ... Weinberger, M. (2014). Redistribution of health care costs after the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2005. *Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer*, 9(4), 512–518. <http://doi.org/10.1097/JTO.000000000000102>
- 320.** Ekstrom, M. P., Bornefalk-Hermansson, A., Abernethy, A. P., & Currow, D. C. (2014). Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. *BMJ (Clinical Research Ed.)*, 348, g445.
- 321.** Girgis, A., Abernethy, A. P., & Currow, D. C. (2014). Caring at the end of life: do cancer caregivers differ from other caregivers? *BMJ Supportive & Palliative Care*. <http://doi.org/10.1136/bmjspcare-2013-000495>
- 322.** Hanson, L. C., Bull, J., Wessell, K., Massie, L., Bennett, R. E., Kutner, J. S., ... Abernethy, A. (2014). Strategies to support recruitment of patients with life-limiting illness for research: the Palliative Care Research Cooperative Group. *Journal of Pain and Symptom Management*, 48(6), 1021–1030. <http://doi.org/10.1016/j.jpainsymman.2014.04.008>
- 300.** Harrison, M. R., Hirsch, B. R., George, D. J., Walker, M. S., Chen, C., Korytowsky, B., ... Abernethy, A. P. (2014). Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry. *Journal of Oncology Practice / American Society of Clinical Oncology*, 10(2), e63–72. <http://doi.org/10.1200/JOP.2013.001180>
- 323.** Havrilesky, L. J., Alvarez Secord, A., Ehrisman, J. A., Berchuck, A., Valea, F. A., Lee, P. S., ... Reed, S. D. (2014). Patient preferences in advanced or recurrent ovarian cancer. *Cancer*, 120(23), 3651–3659. <http://doi.org/10.1002/cncr.28940>
- 324.** Hay, J. L., Atkinson, T. M., Reeve, B. B., Mitchell, S. A., Mendoza, T. R., Willis, G., ... Basch, E. (2014). Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation*, 23(1), 257–269. <http://doi.org/10.1007/s11136-013-0470-1>
- 325.** Hirsch, B. R., Harrison, M. R., George, D. J., Walker, M. S., Chen, C., Korytowsky, B., ... Abernethy, A. P. (2014). Use of “Real-World” data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice. *Medical Oncology (Northwood, London, England)*, 31(9), 156. <http://doi.org/10.1007/s12032-014-0156-8>
- 326.** Howie, L., Hirsch, B., Locklear, T., & Abernethy, A. P. (2014). Assessing the value of patient-generated data to comparative effectiveness research. *Health Affairs (Project Hope)*, 33(7), 1220–1228. <http://doi.org/10.1377/hlthaff.2014.0225>
- 327.** Jensen, R. E., Snyder, C. F., Abernethy, A. P., Basch, E., Potosky, A. L., Roberts, A. C., ... Reeve, B. B. (2014). Review of electronic patient-reported outcomes systems used in cancer clinical care. *Journal of Oncology Practice / American Society of Clinical Oncology*, 10(4), e215–22. <http://doi.org/10.1200/JOP.2013.001067>

- 328.** Johnson, M. J., Bland, J. M., Davidson, P. M., Newton, P. J., Oxberry, S. G., Abernethy, A. P., & Currow, D. C. (2014). The relationship between two performance scales: New York Heart Association Classification and Karnofsky Performance Status Scale. *Journal of Pain and Symptom Management*, 47(3), 652–658. <http://doi.org/10.1016/j.jpainsymman.2013.05.006>
- 329.** Johnson, M. J., Bland, J. M., Oxberry, S. G., Abernethy, A. P., & Currow, D. C. (2014, December). Measuring improvement in dyspnoea: should absolute or relative values be used? *The European Respiratory Journal*. England. <http://doi.org/10.1183/09031936.00108014>
- 330.** Kamal, A. H., Gradison, M., Maguire, J. M., Taylor, D., & Abernethy, A. P. (2014). Quality measures for palliative care in patients with cancer: a systematic review. *Journal of Oncology Practice / American Society of Clinical Oncology*, 10(4), 281–287. <http://doi.org/10.1200/JOP.2013.001212>
- 331.** Kavalieratos, D., Kamal, A. H., Abernethy, A. P., Biddle, A. K., Carey, T. S., Dev, S., ... Weinberger, M. (2014). Comparing unmet needs between community-based palliative care patients with heart failure and patients with cancer. *Journal of Palliative Medicine*, 17(4), 475–481. <http://doi.org/10.1089/jpm.2013.0526>
- 332.** Kavalieratos, D., Mitchell, E. M., Carey, T. S., Dev, S., Biddle, A. K., Reeve, B. B., ... Weinberger, M. (2014). “Not the ‘grim reaper service’”: an assessment of provider knowledge, attitudes, and perceptions regarding palliative care referral barriers in heart failure. *Journal of the American Heart Association*, 3(1), e000544. <http://doi.org/10.1161/JAHA.113.000544>
- 333.** Kravchenko, J., Akushevich, I., Abernethy, A. P., Holman, S., Ross, W. G. J., & Lyster, H. K. (2014). Long-term dynamics of death rates of emphysema, asthma, and pneumonia and improving air quality. *International Journal of Chronic Obstructive Pulmonary Disease*, 9, 613–627. <http://doi.org/10.2147/COPD.S59995>
- 334.** Lai, J.-S., Jensen, S. E., Beaumont, J. L., Abernethy, A. P., Jacobsen, P. B., Syrjala, K., ... Cella, D. (2014). Development of a symptom index for patients with primary brain tumors. *Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research*, 17(1), 62–69. <http://doi.org/10.1016/j.jval.2013.11.006>
- 335.** LeBlanc, T., Kamal, A., & Abernethy, A. (2014, June). Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live? *The Lancet. Oncology*. England. [http://doi.org/10.1016/S1470-2045\(14\)70215-3](http://doi.org/10.1016/S1470-2045(14)70215-3)
- 336.** LeBlanc, T. W., & Abernethy, A. P. (2014). Building the palliative care evidence base: Lessons from a randomized controlled trial of oxygen vs room air for refractory dyspnea. *Journal of the National Comprehensive Cancer Network : JNCCN*, 12(7), 989–992.
- 337.** LeBlanc, T. W., Back, A. L., Danis, M., & Abernethy, A. P. (2014). Electronic Health Records (EHRs) in the oncology clinic: how clinician interaction with EHRs can improve communication with the patient. *Journal of Oncology Practice / American Society of Clinical Oncology*, 10(5), 317–321. <http://doi.org/10.1200/JOP.2014.001385>
- 338.** LeBlanc, T. W., Currow, D. C., & Abernethy, A. P. (2014, March). On Goldilocks, care coordination, and palliative care: making it “just right”. *Primary Care Respiratory Journal : Journal of the General Practice Airways Group*. England. <http://doi.org/10.4104/pcrj.2014.00017>
- 339.** Mitchell, A. P., Hirsch, B. R., & Abernethy, A. P. (2014). Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis. *Trials*, 15, 92. <http://doi.org/10.1186/1745-6215-15-92>
- 340.** Moroni, M., Zocchi, D., Bolognesi, D., Abernethy, A., Rondelli, R., Savorani, G., ... Biasco, G. (2014). The “surprise” question in advanced cancer patients: A prospective study

among general practitioners. *Palliative Medicine*, 28(7), 959–964.  
<http://doi.org/10.1177/0269216314526273>

**341.** Russell, B. J., Rowett, D., Abernethy, A. P., & Currow, D. C. (2014). Prescribing for comorbid disease in a palliative population: focus on the use of lipid-lowering medications. *Internal Medicine Journal*, 44(2), 177–184. <http://doi.org/10.1111/imj.12340>

**342.** Smith, S. K., Rowe, K., & Abernethy, A. P. (2014). Use of an electronic patient-reported outcome measurement system to improve distress management in oncology. *Palliative & Supportive Care*, 12(1), 69–73. <http://doi.org/10.1017/S1478951513000345>

**343.** Taylor, D. H. J., Danis, M., Zafar, S. Y., Howie, L. J., Samsa, G. P., Wolf, S. P., & Abernethy, A. P. (2014). There is a mismatch between the medicare benefit package and the preferences of patients with cancer and their caregivers. *Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology*, 32(28), 3163–3168.  
<http://doi.org/10.1200/JCO.2013.54.2605>

**344.** Wysham, N. G., Abernethy, A. P., & Cox, C. E. (2014). Setting the vision: applied patient-reported outcomes and smart, connected digital healthcare systems to improve patient-centered outcomes prediction in critical illness. *Current Opinion in Critical Care*, 20(5), 566–572.  
<http://doi.org/10.1097/MCC.0000000000000139>

**345.** Zafar, S. Y., Tulskey, J. A., & Abernethy, A. P. (2014). It's time to have "the talk": cost communication and patient-centered care. *Oncology (Williston Park, N. Y.)*, 28(6), 479–480.

**346.** Zullig, L. L., Vanderburg, S. B., Muiruri, C., Abernethy, A., Weiner, B. J., & Bartlett, J. (2014). Sustainability of cancer registration in the Kilimanjaro Region of Tanzania--a qualitative assessment. *World Health & Population*, 15(1), 21–30.

## **[Citation management process changed for all those in 2015-late 2018 in order to accommodate updated software and online processes.]**

347. Phillips J, Dal Grande E, Ritchie C, Abernethy AP, Currow DC. A Population-Based Cross-Sectional Study That Defined Normative Population Data for the Life-Space Mobility Assessment-Composite Score. *J Pain Symptom Manage*. 2015;49(5):885-893. doi:10.1016/j.jpainsymman.2014.09.010

348. Boland J, Currow DC, Wilcock A, et al. A systematic review of strategies used to increase recruitment of people with cancer or organ failure into clinical trials: implications for palliative care research. *J Pain Symptom Manage*. 2015;49(4):762-772.e5. doi:10.1016/j.jpainsymman.2014.09.018

349. Kamal AH, Nipp RD, Bull J, Stinson CS, Abernethy AP. Symptom Burden and Performance Status among Community-Dwelling Patients with Serious Illness. *J Palliat Med*. 2015;18(6):542-544. doi:10.1089/jpm.2014.0381

350. LeBlanc TW, Nickolich M, Rushing CN, Samsa GP, Locke SC, Abernethy AP. What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer. *Support Care Cancer*. 2015;23(12):3455-3463. doi:10.1007/s00520-015-2699-4

351. Hui D, Bansal S, Strasser F, et al. Indicators of integration of oncology and palliative care programs: an international consensus. *Ann Oncol Off J Eur Soc Med Oncol*. 2015;26(9):1953-1959. doi:10.1093/annonc/mdv269

352. Ekström M, Nilsson F, Abernethy AA, Currow DC. Effects of opioids on breathlessness



- and exercise capacity in chronic obstructive pulmonary disease. A systematic review. *Ann Am Thorac Soc*. 2015;12(7):1079-1092. doi:10.1513/AnnalsATS.201501-034OC
353. Lyerly HK, Fawzy MR, Aziz Z, et al. Regional variation in identified cancer care needs of early-career oncologists in China, India, and Pakistan. *Oncologist*. 2015;20(5):532-538. doi:10.1634/theoncologist.2014-0213
  354. Burns EJ, Quinn SJ, Abernethy AP, Currow DC. Caregiver Expectations: Predictors of a Worse Than Expected Caregiving Experience at the End of Life. *J Pain Symptom Manage*. 2015;50(4):453-461. doi:10.1016/j.jpainsymman.2015.04.017
  355. Wysham NG, Miriovsky BJ, Currow DC, et al. Practical Dyspnea Assessment: Relationship Between the 0-10 Numerical Rating Scale and the Four-Level Categorical Verbal Descriptor Scale of Dyspnea Intensity. *J Pain Symptom Manage*. 2015;50(4):480-487. doi:10.1016/j.jpainsymman.2015.04.015
  356. Somers TJ, Abernethy AP, Edmond SN, et al. A Pilot Study of a Mobile Health Pain Coping Skills Training Protocol for Patients With Persistent Cancer Pain. *J Pain Symptom Manage*. 2015;50(4):553-558. doi:10.1016/j.jpainsymman.2015.04.013
  357. Nipp RD, Currow DC, Cherny NI, Strasser F, Abernethy AP, Zafar SY. Best supportive care in clinical trials: review of the inconsistency in control arm design. *Br J Cancer*. 2015;113(1):6-11. doi:10.1038/bjc.2015.192
  358. Hess CN, Roe MT, Clare RM, et al. Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention. *J Am Heart Assoc*. 2015;4(7). doi:10.1161/JAHA.115.001779
  359. Ekström M, Bornefalk-Hermansson A, Abernethy A, Currow D. Low-dose opioids should be considered for symptom relief also in advanced chronic obstructive pulmonary disease (COPD). *Evid Based Med*. 2015;20(1):39. doi:10.1136/ebmed-2014-110130
  360. LeBlanc TW, McNeil MJ, Kamal AH, Currow DC, Abernethy AP. Polypharmacy in patients with advanced cancer and the role of medication discontinuation. *Lancet Oncol*. 2015;16(7):e333-41. doi:10.1016/S1470-2045(15)00080-7
  361. Kamal AH, Kavalieratos D, Bull J, Stinson CS, Nicolla J, Abernethy AP. Usability and Acceptability of the QDACT-PC, an Electronic Point-of-Care System for Standardized Quality Monitoring in Palliative Care. *J Pain Symptom Manage*. 2015;50(5):615-621. doi:10.1016/j.jpainsymman.2015.05.013
  362. Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *JAMA Oncol*. 2015;1(8):1051-1059. doi:10.1001/jamaoncol.2015.2639
  363. Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR. Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. *J Oncol Pract*. 2015;11(6):491-497. doi:10.1200/JOP.2015.004929
  364. Kutner JS, Ritchie CS, Abernethy AP. Selecting the Optimal Design for Drug Discontinuation Trials in a Setting of Advanced, Life-Limiting Illness-Reply. *JAMA Intern Med*. 2015;175(10):1725-1726. doi:10.1001/jamainternmed.2015.4003
  365. Smith SK, Selig W, Harker M, et al. Patient Engagement Practices in Clinical Research among Patient Groups, Industry, and Academia in the United States: A Survey. Zhou X, ed. *PLoS One*. 2015;10(10):e0140232. doi:10.1371/journal.pone.0140232
  366. Zafar SY, Chino F, Ubel PA, et al. The utility of cost discussions between patients with cancer and oncologists. *Am J Manag Care*. 2015;21(9):607-615. <http://www.ncbi.nlm.nih.gov/pubmed/26618364>. Accessed November 30, 2018.
  367. LeBlanc TW, Samsa GP, Wolf SP, Locke SC, Cella DF, Abernethy AP. Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS). *Support Care Cancer*. 2015;23(8):2341-2347.

- doi:10.1007/s00520-015-2606-z
368. Ekström MP, Abernethy AP, Currow DC. The management of chronic breathlessness in patients with advanced and terminal illness. *BMJ*. 2015;350(jan02 2):g7617. doi:10.1136/bmj.g7617
  369. Smith SK, O'Donnell JD, Abernethy AP, MacDermott K, Staley T, Samsa GP. Evaluation of Pillars4life: a virtual coping skills program for cancer survivors. *Psychooncology*. 2015;24(11):1407-1415. doi:10.1002/pon.3750
  370. Burns CM, Dal Grande E, Tieman J, Abernethy AP, Currow DC. Who provides care for people dying of cancer? A comparison of a rural and metropolitan cohort in a South Australian bereaved population study. *Aust J Rural Health*. 2015;23(1):24-31. doi:10.1111/ajr.12168
  371. Secord AA, Coleman RL, Havrilesky LJ, Abernethy AP, Samsa GP, Cella D. Patient-reported outcomes as end points and outcome indicators in solid tumours. *Nat Rev Clin Oncol*. 2015;12(6):358-370. doi:10.1038/nrclinonc.2015.29
  372. Mitchell AP, Hirsch BR, Harrison MR, Abernethy AP, George DJ. Deferred systemic therapy in patients with metastatic renal cell carcinoma. *Clin Genitourin Cancer*. 2015;13(3):e159-66. doi:10.1016/j.clgc.2014.12.017
  373. Kutner JS, Blatchford PJ, Taylor DH, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. *JAMA Intern Med*. 2015;175(5):691-700. doi:10.1001/jamainternmed.2015.0289
  374. Hui D, Bansal S, Strasser F, et al. Reply to the letter to the editor "Integration between oncology and palliative care: does one size fit all?" by Verna et al. *Ann Oncol Off J Eur Soc Med Oncol*. 2016;27(3):549-550. doi:10.1093/annonc/mdv584
  375. Nipp RD, Zullig LL, Samsa G, et al. Identifying cancer patients who alter care or lifestyle due to treatment-related financial distress. *Psychooncology*. 2016;25(6):719-725. doi:10.1002/pon.3911
  376. Kamal AH, Bull JH, Wolf SP, et al. Prevalence and Predictors of Burnout Among Hospice and Palliative Care Clinicians in the U.S. *J Pain Symptom Manage*. 2016;51(4):690-696. doi:10.1016/j.jpainsymman.2015.10.020
  377. Samsa GP, Wolf S, LeBlanc TW, Abernethy AP. An Exploratory Factor Analysis of the Scale Structure of the Patient Care Monitor Version 2.0. *J Pain Symptom Manage*. 2016;51(4):776-783.e2. doi:10.1016/j.jpainsymman.2015.11.013
  378. Currow DC, Abernethy AP, Allcroft P, et al. The need to research refractory breathlessness. *Eur Respir J*. 2016;47(1):342-343. doi:10.1183/13993003.00653-2015
  379. Sawyer T, Nelson MJ, McKee V, et al. Implementing Electronic Tablet-Based Education of Acute Care Patients. *Crit Care Nurse*. 2016;36(1):60-70. doi:10.4037/ccn2016541
  380. Nussbaum N, George DJ, Abernethy AP, et al. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. *Prostate Cancer Prostatic Dis*. 2016;19(2):111-121. doi:10.1038/pcan.2015.42
  381. Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. *Lancet Oncol*. 2016;17(4):519-531. doi:10.1016/S1470-2045(15)00558-6
  382. Hwang ES, Locklear TD, Rushing CN, et al. Patient-Reported Outcomes After Choice for Contralateral Prophylactic Mastectomy. *J Clin Oncol*. 2016;34(13):1518-1527. doi:10.1200/JCO.2015.61.5427
  383. Hirsch BR, Locke SC, Abernethy AP. Experience of the National Cancer Institute Community Cancer Centers Program on Community-Based Cancer Clinical Trials Activity. *J Oncol Pract*. 2016;12(4):e350-8. doi:10.1200/JOP.2015.005090
  384. Berger ML, Curtis MD, Smith G, Harnett J, Abernethy AP. Opportunities and challenges in leveraging electronic health record data in oncology. *Future Oncol*. 2016;12(10):1261-

1274. doi:10.2217/fon-2015-0043
385. Middleton MR, Dalle S, Claveau J, et al. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study. *Cancer Med.* 2016;5(7):1436-1443. doi:10.1002/cam4.717
  386. McNeil MJ, Kamal AH, Kutner JS, Ritchie CS, Abernethy AP. The Burden of Polypharmacy in Patients Near the End of Life. *J Pain Symptom Manage.* 2016;51(2):178-83.e2. doi:10.1016/j.jpainsymman.2015.09.003
  387. McKay C, Burke T, Cao X, Abernethy AP, Carbone DP. Treatment Patterns for Advanced Non-Small-cell Lung Cancer After Platinum-containing Therapy in U.S. Community Oncology Clinical Practice. *Clin Lung Cancer.* 2016;17(5):449-460.e7. doi:10.1016/j.clcc.2016.03.008
  388. Benedict SH, Hoffman K, Martel MK, et al. Overview of the American Society for Radiation Oncology-National Institutes of Health-American Association of Physicists in Medicine Workshop 2015: Exploring Opportunities for Radiation Oncology in the Era of Big Data. *Int J Radiat Oncol Biol Phys.* 2016;95(3):873-879. doi:10.1016/j.ijrobp.2016.03.006
  389. Bickel KE, McNiff K, Buss MK, et al. Defining High-Quality Palliative Care in Oncology Practice: An American Society of Clinical Oncology/American Academy of Hospice and Palliative Medicine Guidance Statement. *J Oncol Pract.* 2016;12(9):e828-38. doi:10.1200/JOP.2016.010686
  390. Hochman MJ, Kamal AH, Wolf SP, et al. Anticholinergic Drug Burden in Noncancer Versus Cancer Patients Near the End of Life. *J Pain Symptom Manage.* 2016;52(5):737-743.e3. doi:10.1016/j.jpainsymman.2016.03.020
  391. Kelleher SA, Somers TJ, Locklear T, Crosswell AD, Abernethy AP. Using Patient Reported Outcomes in Oncology Clinical Practice. *Scand J pain.* 2016;13:6-11. doi:10.1016/j.sjpain.2016.05.035
  392. Ekström M, Ahmadi Z, Bornefalk-Hermansson A, Abernethy A, Currow D. Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy. *Cochrane database Syst Rev.* 2016;11:CD006429. doi:10.1002/14651858.CD006429.pub3
  393. Somers TJ, Kelleher SA, Westbrook KW, et al. A Small Randomized Controlled Pilot Trial Comparing Mobile and Traditional Pain Coping Skills Training Protocols for Cancer Patients with Pain. *Pain Res Treat.* 2016;2016:2473629. doi:10.1155/2016/2473629
  394. Smith AK, Currow DC, Abernethy AP, et al. Prevalence and Outcomes of Breathlessness in Older Adults: A National Population Study. *J Am Geriatr Soc.* 2016;64(10):2035-2041. doi:10.1111/jgs.14313
  395. Watts GJ, Clark K, Agar M, et al. Study protocol: a phase III randomised, double-blind, parallel arm, stratified, block randomised, placebo-controlled trial investigating the clinical effect and cost-effectiveness of sertraline for the palliative relief of breathlessness in people with ch. *BMJ Open.* 2016;6(11):e013177. doi:10.1136/bmjopen-2016-013177
  396. LeBlanc TW, Howson A, Turell W, et al. Risk stratification, treatment selection, and transplant eligibility in multiple myeloma: a qualitative study of the perspectives and self-reported practices of oncologists. *Curr Oncol.* 2016;23(6):e598-e604. doi:10.3747/co.23.3298
  397. Kamal AH, Bull J, Wolf S, et al. Characterizing the Hospice and Palliative Care Workforce in the U.S.: Clinician Demographics and Professional Responsibilities. *J Pain Symptom Manage.* 2016;51(3):597-603. doi:10.1016/j.jpainsymman.2015.10.016
  398. Wysham NG, Howie L, Patel K, et al. Development and Refinement of a Learning Health Systems Training Program. *EGEMS (Washington, DC).* 2016;4(1):1236. doi:10.13063/2327-9214.1236
  399. Martins RT, Currow DC, Abernethy AP, Johnson MJ, Toson B, Eckert DJ. Effects of low-

- dose morphine on perceived sleep quality in patients with refractory breathlessness: A hypothesis generating study. *Respirology*. 2016;21(2):386-391. doi:10.1111/resp.12681
400. Ferreira DH, Silva JP, Quinn S, et al. Blinded Patient Preference for Morphine Compared to Placebo in the Setting of Chronic Refractory Breathlessness—An Exploratory Study. *J Pain Symptom Manage*. 2016;51(2):247-254. doi:10.1016/j.jpainsymman.2015.10.005
  401. Kamal AH, Bull J, Kavalieratos D, et al. Development of the Quality Data Collection Tool for Prospective Quality Assessment and Reporting in Palliative Care. *J Palliat Med*. 2016;19(11):1148-1155. doi:10.1089/jpm.2016.0036
  402. Nardi EA, Lentz LK, Winckworth-Prejsnar K, Abernethy AP, Carlson RW. Emerging Issues and Opportunities in Health Information Technology. *J Natl Compr Canc Netw*. 2016;14(10):1226-1233. <http://www.ncbi.nlm.nih.gov/pubmed/27697977>. Accessed November 30, 2018.
  403. Allen SA, Dal Grande E, Abernethy AP, Currow DC. Two colliding epidemics - obesity is independently associated with chronic pain interfering with activities of daily living in adults 18 years and over; a cross-sectional, population-based study. *BMC Public Health*. 2016;16(1):1034. doi:10.1186/s12889-016-3696-3
  404. Long G V, Atkinson V, Ascierto PA, et al. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. *Ann Oncol Off J Eur Soc Med Oncol*. 2016;27(10):1940-1946. doi:10.1093/annonc/mdw265
  405. Shaw BE, Brazauskas R, Millard HR, et al. Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful. *Cancer*. 2017;123(23):4687-4700. doi:10.1002/cncr.30936
  406. LeBlanc TW, Abernethy AP. Patient-reported outcomes in cancer care - hearing the patient voice at greater volume. *Nat Rev Clin Oncol*. 2017;14(12):763-772. doi:10.1038/nrclinonc.2017.153
  407. Tjia J, Kutner JS, Ritchie CS, et al. Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness. *J Palliat Med*. 2017;20(10):1098-1103. doi:10.1089/jpm.2016.0489
  408. Abernethy AP, Arunachalam A, Burke T, et al. Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. de Mello RA, ed. *PLoS One*. 2017;12(6):e0178420. doi:10.1371/journal.pone.0178420
  409. Phippen NT, Secord AA, Wolf S, et al. Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study. *Gynecol Oncol*. 2017;147(1):98-103. doi:10.1016/j.ygyno.2017.07.121
  410. Schadendorf D, Larkin J, Wolchok J, et al. Health-related quality of life results from the phase III CheckMate 067 study. *Eur J Cancer*. 2017;82:80-91. doi:10.1016/j.ejca.2017.05.031
  411. Bull J, Kamal AH, Harker M, et al. Standardization and Scaling of a Community-Based Palliative Care Model. *J Palliat Med*. 2017;20(11):1237-1243. doi:10.1089/jpm.2017.0027
  412. Abernethy AP, Gippet J, Parulkar R, Revol C. Use of Electronic Health Record Data for Quality Reporting. *J Oncol Pract*. 2017;13(8):530-534. doi:10.1200/JOP.2017.024224
  413. Locklear T, DeBar LL, Willig J, et al. Case Studies from the Clinic: Initiating and Implementing Patient-Reported Outcome Measures. *EGEMS (Washington, DC)*. 2017;5(1):7. doi:10.5334/egems.224
  414. DiGiacomo M, Hatano Y, Phillips J, Lewis J, Abernethy AP, Currow DC. Caregiver characteristics and bereavement needs: Findings from a population study. *Palliat Med*. 2017;31(5):465-474. doi:10.1177/0269216316663855
  415. Karweit J, Kotapati S, Wagner S, Shaw JW, Wolfe SW, Abernethy AP. An expanded

- portfolio of survival metrics for assessing anticancer agents. *Am J Manag Care*. 2017;23(1):54-61. <http://www.ncbi.nlm.nih.gov/pubmed/28141932>. Accessed November 30, 2018.
416. Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. *Ann Oncol Off J Eur Soc Med Oncol*. 2017;28(8):1949-1956. doi:10.1093/annonc/mdx192
  417. Currow DC, Abernethy AP, Fallon M, Portenoy RK. Repurposing Medications for Hospice/Palliative Care Symptom Control Is No Longer Sufficient: A Manifesto for Change. *J Pain Symptom Manage*. 2017;53(3):533-539. doi:10.1016/j.jpainsymman.2016.10.358
  418. Granger BB, Locke SC, Bowers M, et al. The Digital Drag and Drop Pillbox: Design and Feasibility of a Skill-based Education Model to Improve Medication Management. *J Cardiovasc Nurs*. 2017;32(5):E14-E20. doi:10.1097/JCN.0000000000000402
  419. Bhavsar NA, Harrison MR, Hirsch BR, et al. Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer. *Cancer Invest*. 2017;35(5):333-344. doi:10.1080/07357907.2017.1289215
  420. Kelleher SA, Dorfman CS, Plumb Vilardaga JC, et al. Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART. *Contemp Clin Trials*. 2017;57:51-57. doi:10.1016/j.cct.2017.04.001
  421. Miksad RA, Abernethy AP. Harnessing the Power of Real-World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data Quality. *Clin Pharmacol Ther*. 2018;103(2):202-205. doi:10.1002/cpt.946
  422. Butler AM, Cetin K, Hernandez RK, et al. Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States. *Pharmacoepidemiol Drug Saf*. 2018;27(2):229-238. doi:10.1002/pds.4360
  423. Khozin S, Abernethy AP, Nussbaum NC, et al. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval. *Oncologist*. 2018;23(3):328-336. doi:10.1634/theoncologist.2017-0353
  424. Liede A, Wade S, Lethen J, et al. An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer. *Clin Ther*. 2018;40(4):536-549.e3. doi:10.1016/j.clinthera.2017.12.015
  425. Troy JD, de Castro CM, Pupa MR, Samsa GP, Abernethy AP, LeBlanc TW. Patient-Reported Distress in Myelodysplastic Syndromes and Its Association With Clinical Outcomes: A Retrospective Cohort Study. *J Natl Compr Canc Netw*. 2018;16(3):267-273. doi:10.6004/jnccn.2017.7048
  426. Hudson KE, Wolf SP, Samsa GP, Kamal AH, Abernethy AP, LeBlanc TW. The Surprise Question and Identification of Palliative Care Needs among Hospitalized Patients with Advanced Hematologic or Solid Malignancies. *J Palliat Med*. 2018;21(6):789-795. doi:10.1089/jpm.2017.0509
  427. Somers TJ, Kelleher SA, Dorfman CS, et al. An mHealth Pain Coping Skills Training Intervention for Hematopoietic Stem Cell Transplantation Patients: Development and Pilot Randomized Controlled Trial. *JMIR mHealth uHealth*. 2018;6(3):e66. doi:10.2196/mhealth.8565
  428. Yang C-FJ, Aibel K, Meyerhoff R, et al. Actigraphy assessment of sleep quality among patients with acute myeloid leukaemia during induction chemotherapy. *BMJ Support Palliat Care*. 2018;8(3):274-277. doi:10.1136/bmjspcare-2018-001509
  429. Ritchie CS, Kutner JS, Blatchford PJ, Abernethy AP. Response to Davis and Behm (doi: 10.1089/jpm.2017.0608): Discontinuation of Statins. *J Palliat Med*. 2018;21(3):283.

- doi:10.1089/jpm.2017.0661
430. Agarwala V, Khozin S, Singal G, et al. Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study. *Health Aff (Millwood)*. 2018;37(5):765-772. doi:10.1377/hlthaff.2017.1579
  431. Curtis MD, Griffith SD, Tucker M, et al. Development and Validation of a High-Quality Composite Real-World Mortality Endpoint. *Health Serv Res*. 2018;53(6):4460-4476. doi:10.1111/1475-6773.12872
  432. Davis MP, Behm B. Is It Safe to Discontinue Statins? Does Stopping Statins Improve Quality of Life: Yes and No. *J Palliat Med*. 2018;21(3):281-282. doi:10.1089/jpm.2017.0608
  433. O'Connor JM, Fessele KL, Steiner J, et al. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. *JAMA Oncol*. 2018;4(8):e180798. doi:10.1001/jamaoncol.2018.0798
  434. Whitman ED, Liu FX, Cao X, Diede SJ, Haiderali A, Abernethy AP. Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices. *Future Oncol*. September 2018:fon-2018-0620. doi:10.2217/fon-2018-0620
  435. Nass SJ, Rothenberg ML, Pentz R, et al. Accelerating anticancer drug development - opportunities and trade-offs. *Nat Rev Clin Oncol*. 2018;15(12):777-786. doi:10.1038/s41571-018-0102-3
  436. Presley CJ, Tang D, Soulos PR, et al. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. *JAMA*. 2018;320(5):469-477. doi:10.1001/jama.2018.9824
  437. Currow DC, Ekström M, Louw S, et al. Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial. *Eur Respir J*. October 2018:1801270. doi:10.1183/13993003.01270-2018
  438. Winfree KB, Torres AZ, Zhu YE, et al. Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting. *Curr Med Res Opin*. November 2018:1-25. doi:10.1080/03007995.2018.1547273
  439. Burns E, Prigerson HG, Quinn SJ, Abernethy AP, Currow DC. Moving on: Factors associated with caregivers' bereavement adjustment using a random population-based face-to-face survey. *Palliat Med*. 2018;32(1):257-267. doi:10.1177/0269216317717370

**[Citation management process changed for all those in late 2018 to present in order to accommodate updated software and online processes.]**

440. Harnessing the Power of Real-World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data Quality. Miksad RA, Abernethy AP. *Clin Pharmacol Ther*. 2018 Feb;103(2):202-205. doi: 10.1002/cpt.946. Epub 2017 Dec 6. PMID: 29214638 Free PMC article.
441. Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States. Butler AM, Cetin K, Hernandez RK, Diane Reams B, Overman RA, I Kim J, Hirsch BR, Abernethy AP, Liede A, Alan Brookhart M. *Pharmacoepidemiol Drug Saf*. 2018 Feb;27(2):229-238. doi: 10.1002/pds.4360. Epub 2018 Jan 7. PMID: 29316026
442. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.

- Khozin S, Abernethy AP, Nussbaum NC, Zhi J, Curtis MD, Tucker M, Lee SE, Light DE, Gossai A, Sorg RA, Torres AZ, Patel P, Blumenthal GM, Pazdur R. *Oncologist*. 2018 Mar;23(3):328-336. doi: 10.1634/theoncologist.2017-0353. Epub 2018 Jan 9. PMID: 29317551 Free PMC article.
443. An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer. Liede A, Wade S, Lethen J, Hernandez RK, Warner D, Abernethy AP, Finelli A. *Clin Ther*. 2018 Apr;40(4):536-549.e3. doi: 10.1016/j.clinthera.2017.12.015. Epub 2018 Feb 1. PMID: 29395290
  444. The Surprise Question and Identification of Palliative Care Needs among Hospitalized Patients with Advanced Hematologic or Solid Malignancies. Hudson KE, Wolf SP, Samsa GP, Kamal AH, Abernethy AP, LeBlanc TW. *J Palliat Med*. 2018 Jun;21(6):789-795. doi: 10.1089/jpm.2017.0509. Epub 2018 Feb 8. PMID: 29420142 Free PMC article.
  445. Patient-Reported Distress in Myelodysplastic Syndromes and Its Association With Clinical Outcomes: A Retrospective Cohort Study. Troy JD, de Castro CM, Pupa MR, Samsa GP, Abernethy AP, LeBlanc TW. *J Natl Compr Canc Netw*. 2018 Mar;16(3):267-273. doi: 10.6004/jnccn.2017.7048. PMID: 29523665 Free PMC article.
  446. Response to Davis and Behm (doi: 10.1089/jpm.2017.0608): Discontinuation of Statins. Ritchie CS, Kutner JS, Blatchford PJ, Abernethy AP. *J Palliat Med*. 2018 Mar;21(3):283. doi: 10.1089/jpm.2017.0661. PMID: 29649384 No abstract available.
  447. An mHealth Pain Coping Skills Training Intervention for Hematopoietic Stem Cell Transplantation Patients: Development and Pilot Randomized Controlled Trial. Somers TJ, Kelleher SA, Dorfman CS, Shelby RA, Fisher HM, Rowe Nichols K, Sullivan KM, Chao NJ, Samsa GP, Abernethy AP, Keefe FJ. *JMIR Mhealth Uhealth*. 2018 Mar 19;6(3):e66. doi: 10.2196/mhealth.8565. PMID: 29555620 Free PMC article.
  448. Actigraphy assessment of sleep quality among patients with acute myeloid leukaemia during induction chemotherapy. Yang CJ, Aibel K, Meyerhoff R, Wang F, Harpole D, Abernethy AP, LeBlanc TW. *BMJ Support Palliat Care*. 2018 Sep;8(3):274-277. doi: 10.1136/bmjspcare-2018-001509. Epub 2018 Apr 11. PMID: 29643104
  449. Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study. Agarwala V, Khozin S, Singal G, O'Connell C, Kuk D, Li G, Gossai A, Miller V, Abernethy AP. *Health Aff (Millwood)*. 2018 May;37(5):765-772. doi: 10.1377/hlthaff.2017.1579. PMID: 29733723 Review.
  450. Development and Validation of a High-Quality Composite Real-World Mortality Endpoint. Curtis MD, Griffith SD, Tucker M, Taylor MD, Capra WB, Carrigan G, Holzman B, Torres AZ, You P, Arnieri B, Abernethy AP. *Health Serv Res*. 2018 Dec;53(6):4460-4476. doi: 10.1111/1475-6773.12872. Epub 2018 May 14. PMID: 29756355 Free PMC article.
  451. Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. Schoen MW, Basch E, Hudson LL, Chung AE, Mendoza TR, Mitchell SA, St Germain D, Baumgartner P, Sit L, Rogak LJ, Shouery M, Shalley E, Reeve BB, Fawzy MR, Bhavsar NA, Cleeland C, Schrag D, Dueck AC, Abernethy AP. *JMIR Hum Factors*. 2018 Jul 16;5(3):e10070. doi: 10.2196/10070. PMID: 30012546 Free PMC article.
  452. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP. *JAMA*. 2018 Aug 7;320(5):469-477. doi: 10.1001/jama.2018.9824. PMID: 30088010 Free PMC article.

453. Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices. Whitman ED, Liu FX, Cao X, Diede SJ, Haiderali A, Abernethy AP. *Future Oncol*. 2019 Feb;15(5):459-471. doi: 10.2217/fon-2018-0620. Epub 2018 Sep 25. PMID: 30251550
454. Accelerating anticancer drug development - opportunities and trade-offs. Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, Harvey RD, Piantadosi S, Bertagnolli MM, Schrag D, Schilsky RL. *Nat Rev Clin Oncol*. 2018 Dec;15(12):777-786. doi: 10.1038/s41571-018-0102-3. PMID: 30275514 Review.
455. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval. Khozin S, Carson KR, Zhi J, Tucker M, Lee SE, Light DE, Curtis MD, Bralic M, Kaganman I, Gossai A, Hofmeister P, Torres AZ, Miksad RA, Blumenthal GM, Pazdur R, Abernethy AP. *Oncologist*. 2019 May;24(5):648-656. doi: 10.1634/theoncologist.2018-0307. Epub 2018 Dec 27. PMID: 30591549 Free PMC article.
456. Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial. Currow DC, Ekström M, Louw S, Hill J, Fazekas B, Clark K, Davidson PM, McDonald C, Sajkov D, McCaffrey N, Doogue M, Abernethy AP, Agar M. *Eur Respir J*. 2019 Jan 17;53(1):1801270. doi: 10.1183/13993003.01270-2018. Print 2019 Jan. PMID: 30361250 Clinical Trial.
457. Coding Error Resulting in Change in Secondary Outcome Scores in Trial of Safety and Benefit of Discontinuing Statin Therapy Among Terminally Ill Patients. Kutner JS, Abernethy AP. *JAMA Intern Med*. 2019 Jan 1;179(1):126. doi: 10.1001/jamainternmed.2018.7162. PMID: 30508023 No abstract available.
458. Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer. Riaz F, Presley CJ, Chiang AC, Longtine JA, Soulos PR, Adelson KB, Herbst RS, Nussbaum NC, Sorg RA, Abernethy AP, Agarwala V, Gross CP. *J Geriatr Oncol*. 2019 Jul;10(4):669-672. doi: 10.1016/j.jgo.2019.01.016. Epub 2019 Feb 2. PMID: 30718180 No abstract available.
459. Associations Between Polypharmacy, Symptom Burden, and Quality of Life in Patients with Advanced, Life-Limiting Illness. Schenker Y, Park SY, Jeong K, Pruskowski J, Kavalieratos D, Resick J, Abernethy A, Kutner JS. *J Gen Intern Med*. 2019 Apr;34(4):559-566. doi: 10.1007/s11606-019-04837-7. Epub 2019 Feb 4. PMID: 30719645 Free PMC article. Clinical Trial.
460. Pruritus in patients with solid tumors: an overlooked supportive care need. Valley JJ, Hudson KE, Locke SC, Wolf SP, Samsa GP, Abernethy AP, LeBlanc TW. *Support Care Cancer*. 2019 Oct;27(10):3897-3904. doi: 10.1007/s00520-019-04693-5. Epub 2019 Feb 14. PMID: 30762144
461. Implementing an Electronic End-of-Life Chemotherapy Utilization Measure. Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, Meropol NJ. *J Oncol Pract*. 2019 Apr;15(4):220-223. doi: 10.1200/JOP.18.00408. Epub 2019 Mar 18. PMID: 30883256 No abstract available.
462. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Chung AE, Shoenbill K, Mitchell SA, Dueck AC, Schrag D, Bruner DW, Minasian LM, St Germain D, O'Mara AM, Baumgartner P, Rogak LJ, Abernethy AP, Griffin AC, Basch EM. *J Am Med Inform Assoc*. 2019 Apr 1;26(4):276-285. doi: 10.1093/jamia/ocy169. PMID: 30840079 Free PMC article.



463. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert EM, Bourque D, O'Connell C, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Alpha-Cobb G, Guria A, He J, Frank S, Nunnally AC, Bailey M, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller VA. *JAMA*. 2019 Apr 9;321(14):1391-1399. doi: 10.1001/jama.2019.3241. PMID: 30964529 Free PMC article.
464. Small But Mighty: The Use of Real-World Evidence to Inform Precision Medicine. Miksad RA, Samant MK, Sarkar S, Abernethy AP. *Clin Pharmacol Ther*. 2019 Jul;106(1):87-90. doi: 10.1002/cpt.1466. Epub 2019 May 21. PMID: 31112289 Free PMC article. No abstract available.
465. A behavioral cancer pain intervention: A randomized noninferiority trial comparing in-person with videoconference delivery. Kelleher SA, Winger JG, Dorfman CS, Ingle KK, Moskovich AA, Abernethy AP, Keefe FJ, Samsa GP, Kimmick GG, Somers TJ. *Psychooncology*. 2019 Aug;28(8):1671-1678. doi: 10.1002/pon.5141. Epub 2019 Jun 19. PMID: 31162756 Clinical Trial.
466. An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer. Stewart M, Norden AD, Dreyer N, Henk HJ, Abernethy AP, Chrischilles E, Kushi L, Mansfield AS, Khozin S, Sharon E, Arunajadai S, Carnahan R, Christian JB, Miksad RA, Sakoda LC, Torres AZ, Valice E, Allen J. *JCO Clin Cancer Inform*. 2019 Jul;3:1-15. doi: 10.1200/CCI.18.00155. PMID: 31335166 Free PMC article.
467. Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set. Griffith SD, Miksad RA, Calkins G, You P, Lipitz NG, Bourla AB, Williams E, George DJ, Schrag D, Khozin S, Capra WB, Taylor MD, Abernethy AP. *JCO Clin Cancer Inform*. 2019 Aug;3:1-13. doi: 10.1200/CCI.19.00013. PMID: 31403818 Free PMC article.
468. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. Khozin S, Miksad RA, Adami J, Boyd M, Brown NR, Gossai A, Kaganman I, Kuk D, Rockland JM, Pazdur R, Torres AZ, Zhi J, Abernethy AP. *Cancer*. 2019 Nov 15;125(22):4019-4032. doi: 10.1002/cncr.32383. Epub 2019 Aug 5. PMID: 31381142 Free PMC article.
469. Summary of literature on pediatric real-world evidence and effectiveness. McMahon A, Quinto K, Abernethy A, Corrigan-Curay J. *JAMA Pediatrics*. In Press. 2021

## Book Chapters

Dr. Abernethy has over 50 book chapters. A listing is available on request.

## Books

1. Pickar GD, **Abernethy AP**. *Dosage Calculations*. 8th ed. Clifton Park, NY: Delmar Learning; 2008. 9<sup>th</sup> ed, Cengage; 2013.
2. Pickar GD, **Abernethy AP**. *Dosage Calculations: A Ratio-Proportion Approach*. 3rd ed. Clifton Park, NY: Delmar Learning; 2010. 4<sup>th</sup> ed, Cengage; 2015.

## **Abstracts**

Dr. Abernethy has over 600 conference abstracts. A listing is available on request.

## **Video and Online Presentations:**

Dr. Abernethy has presented extensively in public, including conferences, online videos, podcasts, and the lay press. Examples below; additional examples available on request.

TedMed 2013: Can Patient Data Have a Second Life?

<https://www.tedmed.com/talks/show?id=64599>

Duke Clinical Research Institute Grand Rounds, May 1 2015: Learning Health Systems in Oncology – Integrating Data from an HIT Industry Perspective

[https://www.youtube.com/watch?v=LBux9QIWN\\_4](https://www.youtube.com/watch?v=LBux9QIWN_4)

Stanford Big Data Conference 2015, June 12 2015: Creating a River of Data

<https://www.bing.com/videos/search?q=amy+abernethy&&view=detail&mid=9333738C634BB8E979B39333738C634BB8E979B3&&FORM=VRDGAR>

Tech Tonics Podcast, September 25 2017: Dosage, Disney & Data

<https://venturevalkyrie.com/new-tech-tonics-podcast-amy-abernethy-dosage-disney-data/>

Juicing with Gary, May 21 2018: Episode 1 - Flatiron Health

<https://www.youtube.com/watch?v=Iz2AYhQJDD8&t=>

NIH Collaboratory Grand Rounds, June 15, 2018: Research at Scale – Exploring What is Possible with High-quality Real-world Data

<http://rethinkingclinicaltrials.org/news/june-15-2018-research-at-scale-exploring-what-is-possible-with-high-quality-real-world-data-examples-from-flatiron-health-amy-p-abernethy-md-mph/>

The Long Run Podcast: Health Data That Can Meet Pharma Standards, September 19, 2018:

<https://timmermanreport.com/2018/09/health-data-that-can-meet-pharma-standards-amy-abernethy-on-the-long-run/>

8<sup>th</sup> Annual Blueprint for Breakthrough Forum: Lynne Zydowsky & FDA Dep Commissioner Amy Abernethy

<https://www.youtube.com/watch?v=2HVafmxmZ0A&eType=EmailBlastContent&eId=08b79f68-f3bc-4527-b627-8af417d7cae5>

Stat News: Watch – Top FDA official talks bringing the Agency into the New Age

<https://www.statnews.com/2020/02/04/fda-amy-abernethy-agency-technology/>

Trials Needed to Assess Anti-malarial Drugs FDA Official Says – WSJ

<https://www.wsj.com/articles/trials-needed-to-assess-antimalarial-drugs-for-treating-coronavirus-fda-official-says-11585066665>

Coronavirus Drugs and Vaccines are Many Months Away, Official Says – WSJ

<https://www.wsj.com/articles/coronavirus-drugs-vaccine-are-many-months-away-health-experts-say-11585086578>

Getting Real-world Data about COVID-19 – Stat News

<https://www.statnews.com/2020/09/17/virtual-event-getting-real-world-data-about-covid-19/>

## ***Academic Responsibilities and Mentoring:***

### ***Institutional Committee Memberships and Appointments***

*Duke University, Duke University School of Medicine, and Duke University Medical Center*

1997 – 1999	<b>Executive Committee of the Medical Staff, Voting Member</b>
1997 – present	Medical Alumnae Council, 1990 Class Agent
1997 – 1999	Pain and Palliative Care Initiative Leadership Group
1997 – 1999	<b>Institutional Committee on Graduate Medical Education, Elected Housestaff Representative</b>
1998 – 1999	Palliative Care Working Group, Founder and Member
1999 – 2000	Pain and Palliative Care Program, Director Search Committee
2003 – 2008	Institutional Committee on Graduate Medical Education, Executive Council Member
2003 – 2005	Cancer Sciences Sub-committee and Cancer Protocol Committee, Duke Comprehensive Cancer Center, Member and Reviewer
2003 – 2008	Women's Advisory Group, Department of Medicine, Executive Member
2003 – 2008	Intercession Task Force – Curriculum Development, Duke School of Medicine
2003 – 2008	Department of Medicine Advisory Board
2004 – 2012	Duke Center for Palliative Care Leadership Committee
2005 – 2009	<b>Academic Council, Elected Member, Duke University</b>
2005 – 2008	Oncology Clinical Services Unit Advisory Board, member
2005 – 2008	Duke Center for Cancer Survivorship, Advisory Council
2005 – 2008	Duke Quality Cancer Care Initiative, Co-Chair, Duke Comprehensive Cancer Center
2005 – 2008	Duke Integrative Oncology Program, Co-Chair, Duke Comprehensive Cancer Center
2006 – 2015	<b>Member, Cancer Prevention, Detection and Control Program, Duke Comprehensive Cancer Center</b>
2007 – 2009	<b>Elected, Executive Committee of the Academic Council, Duke University</b>
2008 – 2010	Appointed by University President Brodhead, Sustainability Committee, Duke University
2008 – 2010	Interim Program Leader, Cancer Prevention, Detection and Control Program, Duke Comprehensive Cancer Center
2010	Appointed by University President Brodhead, Review of the Office of the Counsel, Duke University
2010 – 2011	Appointed by University Provost Lange, Review of Michael Merson, MD, Director of Duke Global Health Institute, Duke University

2011 Appointed to the Search Committee, Executive Director, Duke Integrative Medicine

***Primary Mentor for Hematology Oncology Fellows***

2005 – 2007	Hope Uronis, MD, MA, Duke (also completed Masters in Clinical Research)
2007 – 2009	Syed Y. Zafar, MD, MA, Duke (also completed Masters in Clinical Research)
2010 – 2012	Arif Kamal, MD, MA, Duke (also completed Masters in Clinical Research)
2010 – 2012	Brad Hirsch, MD, MBA, Duke (also completed a Masters in Business Administration)
2010 – 2013	Thomas LeBlanc, MD, Duke (also completing a fellowship in Palliative Medicine)
2011 – 2013	Benjamin Miriovsky, MD, MA, Duke
2013 – 2015	Lynn Howie, MD, MA, Duke
2014 – 2015	Nathan Nussbaum, MD, Duke (co-mentored with Dr. Yousuf Zafar)
2014 – 2015	Kathryn Hudson, MD, Duke (co-mentored with Dr. Thomas LeBlanc)

***Primary Mentor for other Duke Fellows***

2011 – 2013	Dunya Atisha, MD, Division of Plastic, Reconstructive, Maxillofacial and Oral Surgery, Duke Department of Surgery. 2012 Plastic Surgery Foundation Pilot Research Grant, funded for July 1, 2012.
2014 – 2015	Melissa Wells, MD, Duke Division of Rheumatology (co-mentored with Dr. Arif Kamal)
2014 – 2015	Nicholas Wysham, MD, Duke Division of Pulmonary and Critical Care Medicine (co-mentored with Dr. Arif Kamal)

***Primary Mentor for other Duke University School of Medicine Third-Year Research Students***

2012 – 2014	Jonathan O'Donnell
2013 – 2014	Michael McNeil
2014 – 2015	Michael Hochman

***Advisor for K Awardees and Career Development Awards (awarded)***

2010 – 2015	Rebecca Shelby, PhD – Assistant Professor, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine. Topic: “Improving Adherence to Recommended Surveillance in Breast Cancer Survivors. National Cancer Institute K07. Co-advisor.
-------------	---

- 2011 – 2013 Tamara Somers, PhD – Assistant Professor, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine. Topic: Implementation of Effective Behavioral Interventions for Cancer Pain. NIH-funded Comparative Effectiveness Research Mentored Career Development Program (KM1). Co-advisor.
- 2011 – 2013 Nicole Kuderer, MD – Assistant Professor, Department of Medicine, Division of Medical Oncology, Duke University School of Medicine. Topic: Biomarker Development Predictive of Venous Thromboembolism in Cancer Patients - Platform for Improved Health Outcomes Predictions and Personalized Prophylactic Strategies. NIH-funded Comparative Effectiveness Research Mentored Career Development Program (KM1). Co-advisor.
- 2011 – 2015 Syed Y. Zafar, MD, MA - Assistant Professor, Department of Medicine, Division of Medical Oncology, Duke University School of Medicine. Topic: Defining evidence-based supportive care in advanced cancer clinical trials; Mentored Research Scholar Grant (MRSG) from the American Cancer Society (ACS). **Primary Advisor.** Previously I was his primary mentor and advisor when he was a fellow and then transitioned to Junior Faculty, helping him to achieve the MRSG.
- 2011 – 2015 William Wood, MD, PhD, Assistant Professor, Division of Medical Oncology, Department of Medicine, University of North Carolina, Chapel Hill (UNC-CH). Topic: Symptom burden capture in autologous and allogeneic transplant patients. **Primary Advisor.** NIH KL2/BIRCWH Career Development Programs Award. Previously I was his primary mentor and advisor when he was a fellow and then transitioned to Junior Faculty, helping him to achieve the K Award. Expected completion, 2016 (advising ended 2015).
- 2011 – 2013 Betty Tong, MD, MA, Assistant Professor, Division of Thoracic Oncology, Department of Surgery, Duke. Topic: Use of Electronically-Captured Patient Reported Outcomes (ePROs) to Improve Lung Cancer Care. **Primary Advisor.** Previously I was her primary mentor and advisor when she started as Junior Faculty, helping her to achieve the K Award.
- 2011 – 2013 Matthew Peterson, PhD, Assistant Professor, Dept. of Medicine, Division of Geriatrics, School of Medicine, Duke. Topic: Exercise Doses and Cancer in Older Women. NIH-funded Comparative Effectiveness Research Mentored Career Development Program (KM1). Co-advisor.
- 2011 – 2013 Shivanand (Nandan) Lad, MD, PhD, Assistant Professor, Division of Neurosurgery, Department of Surgery, Duke. Topic: Neurosurgery Outcomes and Comparative Effectiveness Research Program. NIH-funded Comparative Effectiveness Research Mentored Career Development Program (KM1). Co-advisor.
- 2012 – 2013 Sophia Smith, PhD, MSW – Research Associate, Duke Cancer Care Research Program. Topic: Leveraging the Rapid Learning Cancer Clinic prototype: Development and implementation of a data-driven cancer psychosocial care triaging model. NIH-funded Comparative Effectiveness Research Mentored Career Development Program (KM1). **Primary Advisor.** Previous she was a Cancer Care Quality Training Program Postdoctoral Fellow at University of North Carolina, Chapel Hill, and I was her primary

supervisor. She joined my research group as a Research Associate in 2011, and was awarded the KM1 in 2012; I was the primary mentor for this KM1.

- 2012 – 2015 Meredith Nahm, PhD - Associate Director, Academic Programs, Duke Center for Health Informatics. Topic: Information Quality in Healthcare. K99/R00 with a 2 year Mentored phase and a 3 Year R00 phase. Co-advisor.
- 2013 – 2015 Thomas LeBlanc, MD MA – Assistant Professor, Department of Medicine, Division of Cellular Therapy and Hematological Malignancies, Duke University School of Medicine. Topic: Prognostic Discordance in Oncology: What's behind the misunderstanding? Career Development Award (CDA) from the National Palliative Care Research Center (NPCRC). **Primary Advisor.** Previously I was his primary mentor and advisor when he was a fellow and then transitioned to Junior Faculty, helping him to achieve the CDA.

#### ***Supervisor for PhD Candidates***

- 2005 – 2006 Liana Castel, MA, PhD. Thesis Title: Longitudinal epidemiology of pain among patients with metastatic breast cancer. University of North Carolina, Chapel Hill, NC, USA. PhD completed June 2006. Co-supervisor. Resulted in a K07 from the NCI in Population Sciences, starting in 2010.
- 2009 – 2011 Michaela Dinan – Doctoral Candidate in Health Policy and Management. Thesis Title: The effect of increased PET imaging on the staging, outcomes, and health care utilization of Medicare non-small cell lung cancer patients. University of North Carolina, Chapel Hill, NC, USA. PhD completed May 2011. Co-supervisor.
- 2010 – 2013 Dio Kavalieratos, Pre-doctoral Candidate, UNC-CH School of Public Health. Thesis Title: Exploring the Role of Palliative Care in Heart Failure: Referral Barriers, Care Gaps, and Quality of Care. University of North Carolina, Chapel Hill, NC, USA. Co-supervisor.
- 2011 – 2015 Caitlin Sheehan, MBBS – Doctoral Candidate in Palliative Care. Thesis Title: Pending. Flinders University, Adelaide, Australia. Co-supervisor.<sup>3</sup>

#### ***Supervisor for Master in Clinical Research Candidates***

- 2005 – 2007 Hope Uronis, MD, MA – Masters in Clinical Research at Duke University Medical Center, Hematology/Oncology Fellow and Health Services Research & Development Fellow. Duke University, Durham, NC, USA. **Primary mentor.**
- 2007 – 2009 Syed Y. Zafar, MD, MA – Masters in Clinical Research at Duke University Medical Center, Hematology/Oncology Fellow and Health Services Research & Development Fellow. Duke University, Durham, NC, USA. **Primary mentor.**

---

<sup>3</sup> Relinquished role when transitioned to Flatiron Health full time.

2010 – 2014 Arif Kamal, MD – Masters in Clinical Research at Duke University Medical Center, Hematology/Oncology Fellow. Duke University, Durham, NC, USA. **Primary mentor.**

#### ***Supervisor for Master in Management, Clinical Informatics Candidates***

2011 Yuan Song, Topic: Electronic patient reported outcomes. **Primary mentor.**  
 2011 Doug Wixted, Topic: Electronic patient reported outcomes. **Primary mentor.**  
 2011 Amanda Butler, Topic: Electronic patient reported outcomes. **Primary mentor.**

#### ***General mentor for faculty, fellows, residents and students at Duke***

2009 – 2015 Yousuf Zafar, MD, MA; Assistant Professor starting July 2009, promoted to Associate Professor in November 2013, Duke University School of Medicine. **Primary mentor.**  
 2009 – 2013 Julia Kravchenko, MD, PhD, Research Associate, Duke Comprehensive Cancer Center. Co-mentor.  
 2010 – 2015 Sophia Smith, PhD, MSW; Research Associate starting July 2010, promoted to Associate Professor in February 2014, Duke University School of Nursing. **Primary mentor.**  
 2010 – 2011 Amy Goetzinger, PhD, Research Associate, Duke Comprehensive Cancer Center. **Primary mentor.**  
 2010 – 2012 Blair Irwin, MD, MBA, Resident in Internal Medicine, Duke University Medical Center. Winner of a 2012 Resident Research Award. **Primary mentor.**  
 2011 – 2012 Leah Rosenberg, MD, Resident in Internal Medicine, Duke University Medical Center. **Primary mentor.**  
 2011 – 2012 Nikolaos Valilis, Senior Undergraduate Thesis, Duke University, Co-supervisor. Title: Intergenerational Healthcare Resource Allocation Preferences in a Cohort of Duke University Students and Their Parents.  
 2011 – 2015 Ryan Nipp, MD, Resident in Internal Medicine, Duke University Medical Center. Winner of a 2012 Resident Research Award. **Primary mentor.** Since June 2013, Ryan has been a fellow at Massachusetts General Hospital; I continued to mentor him while in this role.  
 2011 – 2015 Aaron Mitchell, MD, Resident in Internal Medicine, Duke University Medical Center. Winner of a 2012 Resident Research Award; oral presentation at the annual American Society for Clinical Oncology meeting 2014. **Primary mentor.**  
 2012 – 2015 Arif Kamal, MD, MA; Assistant Professor starting July 2012, Duke University Medical Center. **Primary mentor.**

- |             |  |
|-------------|--|
| 2012 – 2014 | Brad Hirsch, MD, MBA; Assistant Professor starting July 2012, Duke University Medical Center. <b>Primary mentor.</b>   |
| 2013 – 2015 | Thomas LeBlanc, MD, MA; Assistant Professor starting July 2013, Duke University Medical Center. <b>Primary mentor.</b> |

***Mentor for other faculty, fellows, residents and students at University of North Carolina, Chapel Hill***

- |             |  |
|-------------|--|
| 2011 – 2012 | Leah Zellig, MA, Pre-doctoral Candidate, UNC-CH School of Public Health. Co-mentor.  |
| 2011 – 2012 | Ronald Chen, MD, Assistant Professor, Department of Radiation Oncology, University of North Carolina, Chapel Hill (UNC-CH). Co-mentor. |

***Mentor for other faculty, fellows, residents and students elsewhere***

- |             |  |
|-------------|--|
| 2009 – 2014 | Ken Carson, MD, Assistant Professor, Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Co-mentor.   |
| 2009 – 2014 | Alexandra DuPont, PhD, University of California – Los Angeles, Los Angeles, CA. Co-mentor.   |
| 2010 – 2012 | Danielle Ko, MBBS, JD, Fellow, Palliative Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. <b>Primary mentor.</b>   |
| 2012 – 2015 | Lauren Wiebe, MD, Assistant Professor, Medical College of Wisconsin, Milwaukee, WI. <b>Primary mentor.</b> Awarded American Cancer Society Small Grant (May 2012) to develop an ePRO system for Medical College of Wisconsin. American Cancer Society Grant, awarded July 1, 2012. |
| 2012 – 2013 | Hunter Groninger, MD, Staff Clinician, Pain and Palliative Care Division, Clinical Center, National Institutes of Health, Bethesda, MD. <b>Primary mentor, AAHPM Mentoring Program (awarded 2012-2013).</b>  |

***Corporate Relationships:***

**Executive Leadership**

- Flatiron Health, 2014 – 2018 (a health information technology and cancer data company; [www.flatiron.com](http://www.flatiron.com))

**Corporate Board of Directors (publicly traded companies):**

- athenahealth, 2013 – 2018 (a cloud-based electronic health record and back-office healthcare management company; [www.athenahealth.com](http://www.athenahealth.com))
- CareDx, 2018 – 2019 (a transplantation diagnostics company; [www.caredxinc.com](http://www.caredxinc.com))

**Advisor – Start-up Companies and Investment Firms:**



- Highlander Partners, Senior Advisor, 2017 – 2018 (a private equity firm; <http://highlander-partners.com/>)
- SignalPath Research, Advisor, 2016 – 2018 (a clinical trials management software company; <http://signalpath.com/>)
- The One Health Company, also known as FidoCure, Special Advisor, 2017 – 2018; Advisor starting again in May 2021 -- present (a veterinary oncology diagnostic and treatment company; <http://www.theonehealthcompany.com/>)
- RobinCare, Advisor, 2017 – 2018 (a cancer patient navigation software company; <https://getrobincare.com/>)
- KelaHealth, Advisory, 2018 (a peri-surgical risk prediction company; [kelahealth.com](http://kelahealth.com))
- Iterative Scopes, Investor via Brick Road Group LLC, Jun 2021 – present (a gastroenterology computer vision startup company; [iterativescopes.com](http://iterativescopes.com))

**Family and personal organizations:**

- The Abernethy Pickar Family Foundation, 2018 -- present (a family foundation; previously served as President but stepped aside in 2019 when joined FDA; currently lead philanthropic decisions as of May 2021)
- Orange Leaf Associates LLC, 2014-2018 and then 2021 – present (LLC for general consulting for life sciences and healthcare industries including remuneration for speeches and presentations)
- Brick Road Group LLC, 2021 – present (LLC for local investments in healthcare or businesses with a particular focus on community development in Florida and North Carolina)